

# CITATION REPORT

List of articles citing

## Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

DOI: 10.1001/jama.2017.18718

JAMA - Journal of the American Medical Association, 2017, 318, 2306-2316.

**Source:** <https://exaly.com/paper-pdf/67877600/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1268	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. <b>2018</b> , 24, 2559-2573		95
1267	[Basic principles of diagnosis and treatment of gliomas]. <b>2018</b> , 89, 692-698		4
1266	F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. <b>2018</b> , 139, 399-409		28
1265	Sequencing the next generation of glioblastomas. <b>2018</b> , 55, 264-282		14
1264	A Shock to the System: Tumor-Treating Fields Plus Temozolomide for Glioblastoma. <b>2018</b> , 82, E115-E116		
1263	Current state of immunotherapy for glioblastoma. <b>2018</b> , 15, 422-442		466
1262	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. <b>2018</b> , 4, 495-504		86
1261	CNS cancer: TTFields improve survival. <b>2018</b> , 15, 136		2
1260	Tumor treating fields: a new approach to glioblastoma therapy. <b>2018</b> , 137, 447-453		30
1259	Kaum Berzeugend: Schwerionen und Methadon bei Hirntumoren. <b>2018</b> , 20, 49-49		
1258	BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma. <b>2018</b> , 7, CNS10		4
1257	Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis. <b>2018</b> , 160, 1167-1174		8
1256	Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. <b>2018</b> , 45, 1626-1635		12
1255	Cognitive Changes in Cancer Survivors. <b>2018</b> , 38, 795-806		44
1254	Identification of cephalomannine as a drug candidate for glioblastoma via high-throughput drug screening. <b>2018</b> , 62, 17-20		
1253	Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. <b>2018</b> , 2018, 6204676		14
1252	Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp's Trial: More Controversies than Standards?. <b>2018</b> , 52, 121-128		31

1251	Therapie mit elektrischen Wechselfeldern zusätzlich zur Standard-Temozolomidtherapie. <b>2018</b> , 20, 18-19	
1250	Surgery and Evidence-based Treatments in Patients with Newly Diagnosed High-grade Glioma. <b>2018</b> , 34, 443-453	10
1249	Impact of Cognitive Impairment in Patients with Gliomas. <b>2018</b> , 34, 528-546	8
1248	Estimating the Intensity and Anisotropy of Tumor Treating Fields Using Singular Value Decomposition. Towards a More Comprehensive Estimation of Anti-tumor Efficacy. <b>2018</b> , 2018, 4897-4900	7
1247	Tumor Treating Fields: Adjuvant Treatment for High-grade Gliomas. <b>2018</b> , 34, 454-464	6
1246	Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?. <b>2018</b> , 10,	33
1245	Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development. <b>2018</b> , 19,	40
1244	Tumor treating fields increases membrane permeability in glioblastoma cells. <b>2018</b> , 4, 113	33
1243	Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. <b>2018</b> , 58, 405-421	126
1242	Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma. <b>2018</b> , 17, 2598-2609	26
1241	The Effect of Pet Therapy and Artist Interactions on Quality of Life in Brain Tumor Patients: A Cross-Section of Art and Medicine in Dialog. <b>2018</b> , 8,	3
1240	Dacomitinib: an investigational drug for the treatment of glioblastoma. <b>2018</b> , 27, 823-829	9
1239	Tubulin's response to external electric fields by molecular dynamics simulations. <b>2018</b> , 13, e0202141	13
1238	Neuroimaging in patients with high-grade gliomas. <b>2018</b> , 62, 221-224	
1237	Management of diffuse glioma. <b>2018</b> , 47, e199-e212	7
1236	Harnessing the immune system in glioblastoma. <b>2018</b> , 119, 1171-1181	79
1235	Circulating Glioma Cells Exhibit Stem Cell-like Properties. <b>2018</b> , 78, 6632-6642	49
1234	AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). <b>2018</b> , 9, 1074	29

1233	Proliferation arrest, selectivity, and chemosensitivity enhancement of cancer cells treated by a low-intensity alternating electric field. <b>2018</b> , 20, 90	6
1232	Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. <b>2018</b> , 4, 12	20
1231	Drug Repurposing of Metabolic Agents in Malignant Glioma. <b>2018</b> , 19,	21
1230	NF- $\kappa$ B, Mesenchymal Differentiation and Glioblastoma. <b>2018</b> , 7,	30
1229	Do Anti-Oxidants Vitamin D Melatonin, and Alpha-Lipoic Acid Have Synergistic Effects with Temozolomide on Cultured Glioblastoma Cells?. <b>2018</b> , 5,	8
1228	Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. <b>2018</b> , 35, 136	3
1227	Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma. <b>2018</b> , 170, 127-131	6
1226	Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma. <b>2018</b> , 78, 5023-5037	30
1225	Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. <b>2018</b> , 150, 471-477	25
1224	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. <b>2018</b> , 140, 317-328	71
1223	Actin, alpha, cardiac muscle 1 (ACTC1) knockdown inhibits the migration of glioblastoma cells in vitro. <b>2018</b> , 392, 117-121	6
1222	Primary brain tumours in adults. <b>2018</b> , 392, 432-446	469
1221	Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. <b>2018</b> , 116, 505-517	57
1220	Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions. <b>2018</b> , 9, 1345	29
1219	Highlighting the need for reliable clinical trials in glioblastoma. <b>2018</b> , 18, 1031-1040	10
1218	Molecular Targeting of Acid Ceramidase in Glioblastoma: A Review of Its Role, Potential Treatment, and Challenges. <b>2018</b> , 10,	17
1217	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <b>2018</b> , 16, 142	219
1216	Application of tumor treating fields for newly diagnosed glioblastoma: understanding of nationwide practice patterns. <b>2018</b> , 140, 155-158	8

1215 In the Clinic-Glioblastoma. **2018**, 18, 1

1214 Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma. **2018**, 8, 7301

7

1213 Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study. **2018**, 13, 31

7

1212 Incorrect Spelling of an Author's Name and Data Error. *JAMA - Journal of the American Medical Association*, **2018**, 319, 1824

27.4

1211 Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case. **2018**, 119, 58-60

5

1210 Treatment of glioblastoma in adults. **2018**, 11, 1756286418790452

66

1209 Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. **2018**, 7, CNS23

14

1208 First results on the DCVax phase III trial: raising more questions than providing answers. **2018**, 20, 1283-1284

10

1207 Exploring Long Noncoding RNAs in Glioblastoma: Regulatory Mechanisms and Clinical Potentials. **2018**, 2018, 2895958

32

1206 Tumor-treating fields: time for demystification. **2018**, 29, 1628-1630

5

1205 Commentary: BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction with Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. **2019**, 84, 881-882

1

1204 Applications of Human Brain Organoids to Clinical Problems. **2019**, 248, 53-64

57

1203 Survival Outcomes Among Patients With High-Grade Glioma Treated With 5-Aminolevulinic Acid-Guided Surgery: A Systematic Review and Meta-Analysis. **2019**, 9, 620

24

1202 Whole brain radiotherapy with concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma. **2019**, 68, 39-44

13

1201 TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma. **2019**, 18, 2509-2517

8

1200 Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. **2019**, 4, 651-668

49

1199 Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. **2019**, 1-7

7

1198 Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells. **2019**, 44, 1484-1494

2

1197	Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells. <b>2019</b> , 38, 6630-6646	23
1196	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. <b>2019</b> , 36, 43-48	2
1195	Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma. <b>2019</b> , 19, 628	32
1194	The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy. <b>2019</b> , 97, 255-263	13
1193	Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study. <b>2019</b> , 144, 409-417	5
1192	How we treat glioblastoma. <b>2019</b> , 4, e000520	39
1191	Progress Toward Long-Term Survivors of Glioblastoma. <b>2019</b> , 94, 1278-1286	40
1190	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <b>2019</b> , 21, 1447-1457	19
1189	A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. <b>2019</b> , 125, 3790-3800	32
1188	GPD1 Specifically Marks Dormant Glioma Stem Cells with a Distinct Metabolic Profile. <b>2019</b> , 25, 241-257.e8	33
1187	The neurocognitive evaluation in the butterfly glioma patient. A systematic review. <b>2019</b> , 18, 100512	1
1186	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <b>2019</b> , 25, 5799-5807	72
1185	Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. <b>2019</b> , 142, 2352-2366	60
1184	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. <b>2019</b> , 21, 1458-1469	27
1183	CAR T cells for brain tumors: Lessons learned and road ahead. <b>2019</b> , 290, 60-84	86
1182	Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma and in Glioblastoma Bearing Mice. <b>2019</b> , 2019, 1376140	6
1181	Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. <b>2019</b> , 20, 1702-1709	46
1180	Complementary and alternative medicine use in glioma patients in France. <b>2019</b> , 145, 487-499	7

1179	Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience. <b>2020</b> , 7, 185-195	3
1178	Molecular targeted therapy of glioblastoma. <b>2019</b> , 80, 101896	167
1177	Novel Function of lncRNA ADAMTS9-AS2 in Promoting Temozolomide Resistance in Glioblastoma via Upregulating the FUS/MDM2 Ubiquitination Axis. <b>2019</b> , 7, 217	55
1176	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. <b>2019</b> , 7, 1910-1927	36
1175	Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study. <b>2019</b> , 49, 1016-1023	6
1174	Investigation of uniform sized multicellular spheroids raised by microwell arrays after the combined treatment of electric field and anti-cancer drug. <b>2019</b> , 21, 94	5
1173	Temperature control in TTFields therapy of GBM: impact on the duty cycle and tissue temperature. <b>2019</b> , 64, 225008	8
1172	Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis. <b>2019</b> , 11,	16
1171	Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study. <b>2020</b> , 7, 164-175	1
1170	Neues zur Diagnostik und Therapie von Gliomen. <b>2019</b> , 2, 283-298	1
1169	Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies. <b>2019</b> , 24, e1426-e1436	13
1168	Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. <b>2019</b> , 8, e1655360	40
1167	Reversing the Tumor Target: Establishment of a Tumor Trap. <b>2019</b> , 10, 887	9
1166	Receipt of brachytherapy is an independent predictor of survival in glioblastoma in the Surveillance, Epidemiology, and End Results database. <b>2019</b> , 145, 75-83	9
1165	Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. <b>2019</b> , 7,	69
1164	Methylxanthines: Potential Therapeutic Agents for Glioblastoma. <b>2019</b> , 12,	7
1163	Biomarkers and smart intracranial devices for the diagnosis, treatment, and monitoring of high-grade gliomas: a review of the literature and future prospects. <b>2019</b> , 1, vdz013	2
1162	Synergistic combination of chemo-phototherapy based on temozolomide/ICG-loaded iron oxide nanoparticles for brain cancer treatment. <b>2019</b> , 42, 1709-1724	9

1161	Emerging Applications of Artificial Intelligence in Neuro-Oncology. <b>2019</b> , 290, 607-618	87
1160	Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment. <b>2019</b> , 559, 220-227	25
1159	Optimization of tumor treating fields using singular value decomposition and minimization of field anisotropy. <b>2019</b> , 64, 04NT03	8
1158	Alternating Electric Fields (TTFields) Activate Ca1.2 Channels in Human Glioblastoma Cells. <b>2019</b> , 11,	24
1157	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. <b>2019</b> , 11,	11
1156	Central Nervous System Tumors. <b>2019</b> , 1-41	
1155	Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune System. <b>2019</b> , 13, 1179554918825449	15
1154	Potential effects of nicotine on glioblastoma and chemoradiotherapy: a review. <b>2019</b> , 19, 545-555	4
1153	Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma. <b>2019</b> , 21, 100189	8
1152	Radioterapia dei tumori cerebrali primitivi dell'adulto. <b>2019</b> , 19, 1-11	
1151	Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model. <b>2019</b> , 143, 605-611	10
1150	Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse. <b>2019</b> , 10, 460	28
1149	Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. <b>2019</b> , 33, 591-609	135
1148	Glioblastoma. <b>2019</b> , 237-247	
1147	Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial. <b>2019</b> , 104, 1106-1113	47
1146	Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience. <b>2019</b> , 92, e2483-e2491	20
1145	Cognitive Decline Secondary to Therapeutic Brain Radiation-Similarities and Differences to Traumatic Brain Injury. <b>2019</b> , 9,	2
1144	What is the advance of extent of resection in glioblastoma surgical treatment-a systematic review. <b>2019</b> , 5, 2	3



1143	Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo. <b>2019</b> , 21, 1131-1140	21
1142	Fluorescence-Based Measurement of Real-Time Kinetics of Protoporphyrin IX After 5-Aminolevulinic Acid Administration in Human In Situ Malignant Gliomas. <b>2019</b> , 85, E739-E746	26
1141	Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis. <b>2019</b> , 9, 7362	25
1140	Interventions for cognitive problems in adults with brain cancer: A narrative review. <b>2019</b> , 28, e13088	19
1139	Human Biofield Therapy and the Growth of Mouse Lung Carcinoma. <b>2019</b> , 18, 1534735419840797	1
1138	Dose-painted volumetric modulated arc therapy of high-grade glioma using 3,4-dihydroxy-6-[F]fluoro-L-phenylalanine positron emission tomography. <b>2019</b> , 92, 20180901	9
1137	Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients. <b>2019</b> , 11,	12
1136	Systemic dissemination of glioblastoma: literature review. <b>2019</b> , 65, 460-468	15
1135	Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation. <b>2019</b> , 9, 374	73
1134	Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. <b>2019</b> , 22, 1006-1013	12
1133	R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells. <b>2019</b> , 10, 358	15
1132	Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways. <b>2019</b> , 9, 6124	21
1131	The Role of Platelets in Cancer Pathophysiology: Focus on Malignant Glioma. <b>2019</b> , 11,	12
1130	Synergistic Action of Gefitinib and GSK41364A Simultaneously Loaded in Ratiometrically-Engineered Polymeric Nanoparticles for Glioblastoma Multiforme. <b>2019</b> , 8,	7
1129	D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro. <b>2019</b> , 83, 1017-1024	12
1128	Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma. <b>2019</b> , 8, e1577108	26
1127	Clinical and Molecular Characterization of Adult Glioblastomas in Southern Brazil. <b>2019</b> , 78, 297-304	2
1126	Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. <b>2019</b> , 25, 3643-3657	72

1125	Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. <b>2019</b> , 11,	9
1124	The interplay among psychological distress, the immune system, and brain tumor patient outcomes. <b>2019</b> , 28, 44-50	11
1123	Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma. <b>2019</b> , 11,	5
1122	Diffuse intrinsic pontine glioma cells are vulnerable to low intensity electric fields delivered by intratumoral modulation therapy. <b>2019</b> , 143, 49-56	2
1121	Intensity Modulated Radiation Therapy Versus Volumetric Arc Radiation Therapy in the Treatment of Glioblastoma-Does Clinical Benefit Follow Dosimetric Advantage?. <b>2019</b> , 4, 50-56	3
1120	Therapy for glioblastoma: is it working?. <b>2019</b> , 24, 1193-1201	53
1119	The surgical perspective in precision treatment of diffuse gliomas. <b>2019</b> , 12, 1497-1508	10
1118	The Impact of Timing of Concurrent Chemoradiation in Patients With High-Grade Glioma in the Era of the Stupp Protocol. <b>2019</b> , 9, 186	9
1117	Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. <b>2019</b> , 216, 1071-1090	44
1116	Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. <b>2019</b> , 112, 83-93	12
1115	Current State of Immunotherapy for Treatment of Glioblastoma. <b>2019</b> , 20, 24	145
1114	Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review. <b>2019</b> , 56, 6071-6079	9
1113	Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. <b>2019</b> , 11,	83
1112	Intravital imaging of glioma border morphology reveals distinctive cellular dynamics and contribution to tumor cell invasion. <b>2019</b> , 9, 2054	42
1111	Phase I/II trial testing safety and immunogenicity of the multi-peptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. <b>2019</b> , 21, 923-933	47
1110	Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. <b>2019</b> , 10, 42	26
1109	Mining-Guided Machine Learning Analyses Revealed the Latest Trends in Neuro-Oncology. <b>2019</b> , 11,	3
1108	A feasibility study of the Nativis Voyager device in patients with recurrent glioblastoma in Australia. <b>2019</b> , 8, CNS31	1

1107	Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. <b>2019</b> , 25, 4202-4210	96
1106	The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. <b>2019</b> , 10, 200	51
1105	Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma. <b>2019</b> , 12, 147-161	28
1104	Automatic Brain Tumor Segmentation and Overall Survival Prediction Using Machine Learning Algorithms. <b>2019</b> , 406-418	5
1103	Synergistic Effects of Bortezomib-OV Therapy and Anti-Invasive Strategies in Glioblastoma: A Mathematical Model. <b>2019</b> , 11,	7
1102	Apoptosis and cell cycle arrest of hepatocellular carcinoma spheroids treated by an alternating electric field. <b>2019</b> , 35, e2787	3
1101	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. <b>2019</b> , 393, 678-688	207
1100	Improving survival in molecularly selected glioblastoma. <b>2019</b> , 393, 615-617	20
1099	Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. <b>2019</b> , 8, 33	7
1098	Identification of key candidate genes and pathways in glioblastoma by integrated bioinformatical analysis. <b>2019</b> , 18, 3439-3449	6
1097	PELP1 promotes glioblastoma progression by enhancing Wnt/ $\beta$ catenin signaling. <b>2019</b> , 1, vdz042	5
1096	Changes of O-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review. <b>2019</b> , 11,	16
1095	Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging. <b>2019</b> , 19, 76	7
1094	BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells. <b>2019</b> , 10, 881	11
1093	Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. <b>2019</b> , 9, 17794	5
1092	Multivariate Analysis of Preoperative Magnetic Resonance Imaging Reveals Transcriptomic Classification of Glioblastoma Patients. <b>2019</b> , 13, 81	4
1091	Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. <b>2019</b> , 14, 227	4
1090	What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?. <b>2019</b> , 24, 71-73	6

1089	Tumor treating fields for glioblastoma: should it or will it ever be adopted?. <b>2019</b> , 32, 857-863	4
1088	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. <b>2019</b> , 21, 167-178	92
1087	An early feasibility study of the Nativis Voyager device in patients with recurrent glioblastoma: first cohort in US. <b>2019</b> , 8, CNS30	4
1086	Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years. <b>2019</b> , 85, E322-E331	6
1085	Non-Coding RNAs in Glioma. <b>2018</b> , 11,	68
1084	Glioma response assessment: Classic pitfalls, novel confounders, and emerging imaging tools. <b>2019</b> , 92, 20180730	9
1083	Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. <b>2019</b> , 141, 111-120	18
1082	Gliome und ihre medikamentöse Behandlung. <b>2019</b> , 25, 53-59	
1081	Neue Behandlungsoptionen bei Gliomen. <b>2019</b> , 25, 60-66	1
1080	5-ALA and FDA approval for glioma surgery. <b>2019</b> , 141, 479-486	109
1079	Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. <b>2019</b> , 141, 467-473	53
1078	Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma. <b>2019</b> , 39, 1982-1993	37
1077	Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. <b>2019</b> , 19, 64-72	29
1076	Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?. <b>2019</b> , 21, 14-25	45
1075	Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. <b>2019</b> , 125, 424-433	28
1074	Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis. <b>2019</b> , 1866, 175-189	9
1073	Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. <b>2019</b> , 142, 91-101	23
1072	Drug development for glioma: are we repeating the same mistakes?. <b>2019</b> , 20, 10-12	6

1071	Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <b>2019</b> , 25, 1809-1816	59
1070	Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme. <b>2019</b> , 538, 449-461	43
1069	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <b>2019</b> , 21, 95-105	55
1068	Malignancy Index Using Intraoperative Flow Cytometry is a Valuable Prognostic Factor for Glioblastoma Treated With Radiotherapy and Concomitant Temozolomide. <b>2019</b> , 84, 662-672	11
1067	Characterizing the heterogeneity in 5-aminolevulinic acid-induced fluorescence in glioblastoma. <b>2019</b> , 132, 1706-1714	7
1066	Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [F]DASA-23. <b>2020</b> , 22, 124-133	8
1065	Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone. <b>2020</b> , 5, 53-61	10
1064	Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy. <b>2020</b> , 5, 62-69	5
1063	Intraoperative radiotherapy for glioblastoma: an international pooled analysis. <b>2020</b> , 142, 162-167	7
1062	Longitudinal Characteristics of Glioblastoma in Genome-Wide Studies. <b>2020</b> , 26, 2035-2047	4
1061	Radiosensitization of high-grade gliomas through induced hyperthermia: Review of clinical experience and the potential role of MR-guided focused ultrasound. <b>2020</b> , 142, 43-51	13
1060	Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. <b>2020</b> , 146, 55-62	14
1059	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. <b>2020</b> , 22, 470-479	13
1058	Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review. <b>2020</b> , 52, 54-69	26
1057	Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. <b>2020</b> , 34, 127-145	15
1056	Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit. <b>2020</b> , 146, 381-387	6
1055	Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma. <b>2020</b> , 12,	17
1054	Supramaximal resection: A systematic review of its safety, efficacy and feasibility in glioblastoma. <b>2020</b> , 72, 328-334	15

1053	Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. <b>2020</b> , 26, 477-486	32
1052	Current Role of Radiation Therapy in the Management of Malignant Central Nervous System Tumors. <b>2020</b> , 34, 13-28	6
1051	The combination of two-dimensional and three-dimensional analysis methods contributes to the understanding of glioblastoma spatial heterogeneity. <b>2020</b> , 13, e201900196	4
1050	A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors. <b>2020</b> , 2, 100025-100025	13
1049	Macrophage exclusion after radiation therapy (MERT): A new and effective way to increase the therapeutic ratio of radiotherapy. <b>2020</b> , 144, 159-164	10
1048	Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. <b>2020</b> , 146, 163-170	9
1047	Shocking Finding on Head Computed Tomography. <b>2020</b> , 16, 30	0
1046	Olfactory function as an independent prognostic factor in glioblastoma. <b>2020</b> , 94, e529-e537	1
1045	Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. <b>2020</b> , 146, 787-792	13
1044	Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma. <b>2020</b> , 9, 1263-1275	5
1043	Brain immunology and immunotherapy in brain tumours. <b>2020</b> , 20, 12-25	174
1042	Clinical neuro-oncology for the neurologist. <b>2020</b> , 10, 458-465	2
1041	Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients. <b>2020</b> , 146, 157-162	5
1040	Tumor Board Report: The value of tissue diagnosis. <b>2020</b> , 44, 100530	
1039	Multireceptor targeting of glioblastoma. <b>2020</b> , 2, vdaa107	4
1038	Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With -Mutated Glioblastoma and -Deficient Lynch Syndrome. <b>2020</b> , 4,	2
1037	Quo Vadis Oncological Hyperthermia (2020)? <b>2020</b> , 10, 1690	15
1036	Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas. <b>2020</b> , 10,	3

1035 Neues zur Diagnostik und Therapie von Gliomen. **2020**, 2, 35-50

1034 New hints towards a precision medicine strategy for IDH wild-type glioblastoma. **2020**, 31, 1679-1692 14

1033 Low mitochondrial DNA copy number is associated with poor prognosis and treatment resistance in glioblastoma. **2020**, 55, 154-163 3

1032 Novel Treatment Strategies for Glioblastoma. **2020**, 12, 14

1031 Oncolytic Virotherapy in Glioma Tumors. **2020**, 21, 16

1030 OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma. **2020**, 2, vdaa121 4

1029 An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications. **2021**, 97, 1044-1054 6

1028 Physical approaches to treat glioblastoma. **2020**, 32, 640-649 2

1027 Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients. **2020**, 20, 931 2

1026 Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. **2020**, 26, 6600-6609 3

1025 Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis. **2021**, 44, 1943-1955 3

1024 Organotypic Models to Study Human Glioblastoma: Studying the Beast in Its Ecosystem. **2020**, 23, 101633 8

1023 Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma. **2020**, 8, 6

1022 Current clinical management of elderly patients with glioma. **2020**, 20, 1037-1048 1

1021 The IMPACT of Molecular Grading of Gliomas on Contemporary Clinical Practice. **2020**, 107, 859-862 0

1020 Leukemia-Associated Rho Guanine Nucleotide Exchange Factor and Ras Homolog Family Member C Play a Role in Glioblastoma Cell Invasion and Resistance. **2020**, 190, 2165-2176 2

1019 Sequential delivery of dual drugs with nanostructured lipid carriers for improving synergistic tumor treatment effect. **2020**, 27, 983-995 12

1018 The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction. **2020**, 402, 115133 4

1017	Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistance. <b>2020</b> , 21, 174	23
1016	The Multipotential of Leucine-Rich $\beta$ Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma. <b>2020</b> , 79, 873-879	6
1015	Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. <b>2020</b> , 9, 1779990	12
1014	The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. <b>2020</b> , 13,	11
1013	Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment. <b>2020</b> , 10, 575992	7
1012	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma. <b>2020</b> , 150, 269-359	5
1011	A Novel In Vitro Device to Deliver Induced Electromagnetic Fields to Cell and Tissue Cultures. <b>2020</b> , 119, 2378-2390	2
1010	LNx1 Modulates Notch1 Signaling to Promote Expansion of the Glioma Stem Cell Population during Temozolomide Therapy in Glioblastoma. <b>2020</b> , 12,	2
1009	New Avenues in Radiotherapy of Glioblastoma: from Bench to Bedside. <b>2020</b> , 22, 1	
1008	Heat transfer during TTF fields treatment: Influence of the uncertainty of the electric and thermal parameters on the predicted temperature distribution. <b>2020</b> , 196, 105706	4
1007	Assessment of Prognostic Value of Cystic Features in Glioblastoma Relative to Sex and Treatment With Standard-of-Care. <b>2020</b> , 10, 580750	1
1006	Interactions between Tumor Cells, Neurons, and Microglia in the Glioma Microenvironment. <b>2020</b> , 21,	13
1005	Proteasome inhibition for the treatment of glioblastoma. <b>2020</b> , 29, 1133-1141	17
1004	Tumor Treating Fields in the Management of Patients with Malignant Gliomas. <b>2020</b> , 21, 76	19
1003	Alkaloids of faspaplysin are promising chemotherapeutic agents for the treatment of glioblastoma: Review. <b>2020</b> , 151, 299-324	3
1002	NF- $\kappa$ B inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF- $\kappa$ B(p65) and actin cytoskeleton regulatory pathways. <b>2020</b> , 10, 13352	19
1001	Non-thermal effects of radiofrequency electromagnetic fields. <b>2020</b> , 10, 13488	30
1000	Dimeric small molecule agonists of EphA2 receptor inhibit glioblastoma cell growth. <b>2020</b> , 28, 115656	1



999	Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. <b>2020</b> , 10, 1045	9
998	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. <b>2020</b> , 26, 5297-5303	26
997	Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, -mutant glioblastoma: a case report from a Phase I study. <b>2020</b> , 9, CNS62	8
996	Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade. <b>2020</b> , 10, 840	13
995	Personalized and translational approach for malignant brain tumors in the era of precision medicine: the strategic contribution of an experienced neurosurgery laboratory in a modern neurosurgery and neuro-oncology department. <b>2020</b> , 417, 117083	5
994	Diagnose und Therapie der Gliome des Erwachsenen. <b>2020</b> , 23, 65-75	
993	Optimization of multi-electrode implant configurations and programming for the delivery of non-ablative electric fields in intratumoral modulation therapy. <b>2020</b> , 47, 5441-5454	0
992	Ion Channels as Therapeutic Targets in High Grade Gliomas. <b>2020</b> , 12,	9
991	A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. <b>2020</b> , 12,	11
990	Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. <b>2020</b> , 5,	7
989	High-throughput microRNA profile in adult and pediatric primary glioblastomas: the role of miR-10b-5p and miR-630 in the tumor aggressiveness. <b>2020</b> , 47, 6949-6959	2
988	Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?". <b>2020</b> , 22, 1889-1890	1
987	Current usage of tumor treating fields for glioblastoma. <b>2020</b> , 2, vdaa069	12
986	Benign and malignant tumors of the central nervous system and pregnancy. <b>2020</b> , 172, 241-258	1
985	Ipilimumab: an investigational immunotherapy for glioblastoma. <b>2020</b> , 29, 1187-1193	5
984	MicroRNA-93 acts as an "anti-inflammatory tumor suppressor" in glioblastoma. <b>2020</b> , 2, vdaa047	7
983	The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology. <b>2020</b> , 37, 27-34	8
982	Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable. <b>2020</b> , 10,	1

981	Radioresistance in Glioblastoma and the Development of Radiosensitizers. <b>2020</b> , 12,	20
980	Wnt/βcatenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. <b>2020</b> , 11, 771	27
979	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <b>2020</b> , 20, 785-795	13
978	Antitumor Activity of Curcumin in Glioblastoma. <b>2020</b> , 21,	11
977	Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma. <b>2020</b> , 12, 23838-23850	9
976	Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma. <b>2020</b> , 13,	5
975	Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy. <b>2020</b> , 10, 604121	20
974	Characterizing Cell Stress and GRP78 in Glioma to Enhance Tumor Treatment. <b>2020</b> , 10, 608911	3
973	Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. <b>2020</b> , 2, vdaa082	11
972	Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future. <b>2020</b> , 11, 594271	12
971	Glioblastoma treatment guidelines: Consensus by the Spanish Society of Neurosurgery Tumor Section. <b>2020</b> , 31, 289-297	
970	Glioblastoma treatment guidelines: Consensus by the Spanish Society of Neurosurgery Tumor Section. <b>2020</b> , 31, 289-298	4
969	Early Treatment Response Assessment Using F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy. <b>2021</b> , 62, 918-925	8
968	Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas. <b>2020</b> ,	39
967	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. <b>2020</b> , 87, 931-938	2
966	Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients. <b>2020</b> , 26, 4031-4039	9
965	CD8 T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. <b>2020</b> , 26, 4390-4401	9
964	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. <b>2020</b> , 5, CD013238	11

963	Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide. <b>2020</b> , 2020, 4392189	7
962	Management of glioblastoma: State of the art and future directions. <b>2020</b> , 70, 299-312	328
961	Hippocampal-Sparing Radiotherapy for Patients With Glioblastoma and Grade II-III Gliomas. <b>2020</b> , 6, 981-983	4
960	Tumor treating fields for high-grade gliomas. <b>2020</b> , 127, 110193	9
959	Increased effect of two-fraction radiotherapy in conjunction with IDO1 inhibition in experimental glioblastoma. <b>2020</b> , 15, e0233617	3
958	Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma. <b>2020</b> , 11, 835	45
957	Ribosomal protein S11 influences glioma response to TOP2 poisons. <b>2020</b> , 39, 5068-5081	7
956	Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. <b>2020</b> , 148, 489-500	16
955	Impact of neurosurgical enhanced recovery after surgery (ERAS) program on health-related quality of life in glioma patients: a secondary analysis of a randomized controlled trial. <b>2020</b> , 148, 555-567	5
954	Aspirin Induced Glioma Apoptosis through Noxa Upregulation. <b>2020</b> , 21,	7
953	TTDA inhibited apoptosis by regulating the p53-Bax/Bcl2 axis in glioma. <b>2020</b> , 331, 113380	7
952	Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. <b>2020</b> , 18, 142	8
951	A systematic review of tumor treating fields therapy for high-grade gliomas. <b>2020</b> , 148, 433-443	6
950	Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma. <b>2020</b> , 10, 798	12
949	Large-Scale Drug Screening in Patient-Derived IDH Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents. <b>2020</b> , 9,	9
948	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. <b>2020</b> , 26, 5232-5245	27
947	Metabolic heterogeneity and adaptability in brain tumors. <b>2020</b> , 77, 5101-5119	14
946	Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. <b>2020</b> , 148, 577-585	2

945	Against Repurposing Methadone for Glioblastoma Therapy. <b>2020</b> , 10,	5
944	Corneal side effects induced by EGFR-inhibitor antibody-drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study. <b>2020</b> , 12, 1758835920907543	8
943	Serine-dependent redox homeostasis regulates glioblastoma cell survival. <b>2020</b> , 122, 1391-1398	20
942	Tumor Cell Invasion in Glioblastoma. <b>2020</b> , 21,	64
941	Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition. <b>2020</b> , 26, 2381-2392	13
940	Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study. <b>2020</b> , 10, 411	16
939	Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. <b>2020</b> , 147, 297-307	57
938	The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. <b>2020</b> , 12,	28
937	The SHORT Score for Preoperative Assessment of the Risk for Short-Term Survival in Glioblastoma. <b>2020</b> , 138, e370-e380	3
936	Identification and Analysis of Glioblastoma Biomarkers Based on Single Cell Sequencing. <b>2020</b> , 8, 167	15
935	Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. <b>2020</b> , 147, 653-661	10
934	Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. <b>2020</b> , 25,	15
933	Personalized neoantigen vaccines: a glimmer of hope for glioblastoma. <b>2020</b> , 19, 407-417	5
932	Tumor-derived exosomes in the regulation of macrophage polarization. <b>2020</b> , 69, 435-451	70
931	Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients. <b>2020</b> , 10, 89	10
930	Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma. <b>2020</b> , 122, 1146-1157	19
929	Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. <b>2020</b> , 126, 2625-2636	30
928	Identification of Prognostic Signatures of Alternative Splicing in Glioma. <b>2020</b> , 70, 1484-1492	5

927	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <b>2020</b> , 22, 1568-1579	15
926	Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes. <b>2020</b> , 108, 979-986	5
925	JAM-A functions as a female microglial tumor suppressor in glioblastoma. <b>2020</b> , 22, 1591-1601	15
924	Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma. <b>2020</b> , 2, vdz052	4
923	Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm. <b>2020</b> , 15, 531-540	5
922	ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma. <b>2020</b> , 108, 987-995	22
921	Disparities in patient enrollment on glioblastoma clinical trials. <b>2020</b> , 9, CNS59	1
920	Multimodal single-cell analysis reveals distinct radioresistant stem-like and progenitor cell populations in murine glioma. <b>2020</b> , 68, 2486-2502	4
919	A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. <b>2020</b> , 22, 1182-1189	8
918	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. <b>2020</b> , 2, vdaa011	13
917	Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma. <b>2020</b> , 147, 125-133	6
916	Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[F]-fluoroethyl)-L-tyrosine PET. <b>2020</b> , 47, 1486-1495	9
915	AVNP2 protects against cognitive impairments induced by C6 glioma by suppressing tumour associated inflammation in rats. <b>2020</b> , 87, 645-659	6
914	Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13R $\alpha$ -Promoted Invasion and Metastasis in Cancer Cells. <b>2020</b> , 12,	11
913	Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cells. <b>2020</b> , 11, 152	9
912	Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. <b>2020</b> , 12,	33
911	Patterns of management and outcomes of unifocal versus multifocal glioblastoma. <b>2020</b> , 74, 155-159	12
910	Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma. <b>2020</b> , 10, 59	12

909	CXCR4 Antagonists as Stem Cell Mobilizers and Therapy Sensitizers for Acute Myeloid Leukemia and Glioblastoma?. <b>2020</b> , 9,	9
908	Barium Titanate Nanoparticles Sensitise Treatment-Resistant Breast Cancer Cells to the Antitumor Action of Tumour-Treating Fields. <b>2020</b> , 10, 2560	9
907	MicroRNA-mRNA Interactions at Low Levels of Compressive Solid Stress Implicate mir-548 in Increased Glioblastoma Cell Motility. <b>2020</b> , 10, 311	3
906	Tumor antigens in glioma. <b>2020</b> , 47, 101385	19
905	The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas. <b>2020</b> , 10, 9	9
904	Immunotherapy for Malignant Glioma: Current Status and Future Directions. <b>2020</b> , 41, 123-138	44
903	Temozolomide in Combination With NF- $\kappa$ B Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation.. <b>2020</b> , 1, 9-16	3
902	First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. <b>2020</b> , 26, 1820-1828	24
901	Endoplasmic Reticulum Stress Contributes to Indomethacin-Induced Glioma Apoptosis. <b>2020</b> , 21,	13
900	Risk Factors for Early Mortality Among Patients with Glioma: A Population-Based Study. <b>2020</b> , 136, e496-e503	6
899	Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. <b>2020</b> , 47, 1458-1467	30
898	Glioblastoma precision therapy: From the bench to the clinic. <b>2020</b> , 475, 79-91	13
897	Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. <b>2020</b> , 25, 1004-1009	9
896	First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. <b>2020</b> , 146, 451-458	9
895	Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. <b>2020</b> , 146, 399-406	7
894	Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?. <b>2020</b> , 12,	7
893	[Dosimetry of tumor treating fields: energy per unit correlates with oncological endpoints in patients with glioblastoma in the EF-14 trial]. <b>2020</b> , 196, 583-585	
892	Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. <b>2020</b> , 3, CD013261	15

891	Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma. <b>2020</b> , 147, 599-605	9
890	Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic. <b>2020</b> ,	47
889	Case Report of Complete Radiological Response of a Thalamic Glioblastoma After Treatment With Proton Therapy Followed by Temozolomide and Tumor-Treating Fields. <b>2020</b> , 10, 477	3
888	Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. <b>2020</b> , 12,	30
887	The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors. <b>2020</b> , 40, 1-12	2
886	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <b>2020</b> , 22, 1073-1113 <sup>178</sup>	
885	Integrating Genomic Data with Transcriptomic Data for Improved Survival Prediction for Adult Diffuse Glioma. <b>2020</b> , 11, 3794-3802	3
884	Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. <b>2020</b> , 15, e0230492	7
883	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). <b>2020</b> , 22, 1851-1861	31
882	Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner. <b>2020</b> , 10, 1210-1225	49
881	Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. <b>2020</b> , 7, 3-15	2
880	Impact of Peritumoral Edema During Tumor Treatment Field Therapy: A Computational Modelling Study. <b>2020</b> , 67, 3327-3338	2
879	Combined radiotherapy and concurrent tumor treating fields (TTFs) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial. <b>2020</b> , 15, 83	5
878	Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. <b>2020</b> , 26, 3135-3144	5
877	Tumour treating fields therapy for glioblastoma: current advances and future directions. <b>2021</b> , 124, 697-709	32
876	Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. <b>2021</b> , 147, 253-262	1
875	Pulsed radiation therapy for the treatment of newly diagnosed glioblastoma. <b>2021</b> , 23, 447-456	1
874	Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond. <b>2021</b> , 45, 18-53	5

873	Low-viscosity sodium alginate combined with TiO nanoparticles for improving neuroblastoma treatment. <b>2021</b> , 167, 921-933	5
872	Surgery for Glioblastoma in Elderly Patients. <b>2021</b> , 32, 137-148	2
871	Clinical practice guidelines for the management of adult diffuse gliomas. <b>2021</b> , 499, 60-72	61
870	Radiosurgery for Glioblastoma. <b>2021</b> , 32, 117-128	8
869	Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression. <b>2021</b> , 23, 58-67	3
868	What is New in Neuro-oncology?. <b>2021</b> , 39, 163-179	3
867	Surgical Adjuncts for Glioblastoma. <b>2021</b> , 32, 83-91	1
866	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <b>2021</b> , 18, 170-186	204
865	4-Methoxydalbergione is a potent inhibitor of human astrogloma U87 cells in vitro and in vivo. <b>2021</b> , 42, 1507-1515	7
864	Characterization of adherent primary cell lines from fresh human glioblastoma tissue, defining glial fibrillary acidic protein as a reliable marker in establishment of glioblastoma cell culture. <b>2021</b> , 4, e1324	2
863	A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme. <b>2021</b> , 22, 89-100	
862	Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. <b>2021</b> , 112, 81-90	2
861	Activation of 4-1BBL+ B cells with CD40 agonism and IFN $\gamma$ elicits potent immunity against glioblastoma. <b>2021</b> , 218,	16
860	Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches. <b>2021</b> , 4, 2000124	17
859	Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients. <b>2021</b> , 28, 294-306	3
858	Current state and future perspective of drug repurposing in malignant glioma. <b>2021</b> , 68, 92-104	18
857	Rodent Brain Tumor Models for Neuro-Oncology Research. <b>2021</b> , 219-236	
856	Computational Diagnostics of GBM Tumors in the Era of Radiomics and Radiogenomics. <b>2021</b> , 30-38	0



855 Glioma. **2021**, 210-211.e1

854 Glioblastoma: What can we do for these patients today and what will we be able to do in the future?. **2021**, 265, 99-118

853 Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer. **2021**, 3, vdab006

1

852 Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. **2021**, 635-665

851 Temozolomide chrono-therapy in patients with glioblastoma: a retrospective single-institute study. **2021**, 3, vdab041

9

850 Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease. **2021**, 3, vdab028

4

849 The Effects of Electromagnetic Fields on Human Health: Recent Advances and Future. **2021**, 18, 210-237

1

848 Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells. **2021**, 11, 1295-1309

4

847 MR1 overexpression correlates with poor clinical prognosis in glioma patients. **2021**, 3, vdab034

0

846 A Novel Glucose Metabolism-Related Gene Signature for Overall Survival Prediction in Patients with Glioblastoma. **2021**, 2021, 8872977

4

845 Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. **2021**, 12, 1094-1104

4

844 Therapeutic approaches to overcome temozolomide resistance in glioblastoma. **2021**, 507-545

843 Understanding the Role of Plasticity in Glioblastoma. **2021**,

842 Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?. **2021**, 3, vdab008

4

841 Non-thermal membrane effects of electromagnetic fields and therapeutic applications in oncology. **2021**, 38, 715-731

8

840 Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF-phase I/II trial. **2021**, 22, 242-250

0

839 Glioma-associated microglia/macrophages augment tumorigenicity in canine astrocytoma, a naturally occurring model of human glioma. **2021**, 3, vdab062

2

838 The Role of Microglia in Glioblastoma. **2020**, 10, 603495

5

837	Proteoglycans of the Neural Stem Cell Niche. <b>2021</b> , 179-203	
836	Therapeutic strategies of recurrent glioblastoma and its molecular pathways 'Lock up the beast'. <b>2021</b> , 15, 1176	3
835	Potential of naso-brain drug delivery in glioblastoma therapy. <b>2021</b> , 389-404	
834	Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma. <b>2021</b> , 547-585	
833	Current Advances in Immunotherapy for Glioblastoma. <b>2021</b> , 23, 21	9
832	Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development. <b>2021</b> , 10,	18
831	A Review of Newly Diagnosed Glioblastoma. <b>2020</b> , 10, 574012	12
830	The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme. <b>2021</b> , 1-13	1
829	Morphological Metrics of Magnetic Resonance Imaging of Glioblastoma as Biomarkers of Prognosis.	
828	A mesoscopic simulator to uncover heterogeneity and evolutionary dynamics in tumors. <b>2021</b> , 17, e1008266	2
827	Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas. <b>2021</b> , 26,	4
826	Neuronavigation-guided focused ultrasound for transcranial blood-brain barrier opening and immunostimulation in brain tumors. <b>2021</b> , 7,	23
825	Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread. <b>2021</b> , 7, e561	0
824	Observations on the anti-glioma potential of electrical fields: is there a role for surgical neuromodulation?. <b>2021</b> , 1-5	0
823	Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. <b>2021</b> , 8, 299-309	1
822	A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. <b>2021</b> , 124, 1379-1387	19
821	Heterogeneity of radiation response in mesenchymal subtype glioblastoma: molecular profiling and reactive oxygen species generation. <b>2021</b> , 152, 245-255	
820	Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. <b>2021</b> ,	10

819	Immunohistochemical Detection of Neural Stem Cells and Glioblastoma Stem Cells in the Subventricular Zone of Glioblastoma Patients. <b>2021</b> , 69, 349-364	5
818	Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. <b>2021</b> , 13,	10
817	Post-Operative Accelerated-Hypofractionated Chemoradiation With Volumetric Modulated Arc Therapy and Simultaneous Integrated Boost in Glioblastoma: A Phase I Study (ISIDE-BT-2). <b>2020</b> , 10, 626400	1
816	Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas. <b>2021</b> , 70, 2589-2600	1
815	Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity. <b>2021</b> , 118,	2
814	Small-Molecule HSP27 Inhibitor Abolishes Androgen Receptors in Glioblastoma. <b>2021</b> , 64, 1570-1583	3
813	Clinical trials using oncolytic viral therapy to treat adult glioblastoma: a progress report. <b>2021</b> , 50, E3	8
812	Tumortheraiefelder zur Behandlung des Glioblastoms verordnungsffig. <b>2021</b> , 32, 14-15	
811	Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. <b>2021</b> , 27, 2038-2049	6
810	Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. <b>2021</b> , 10,	13
809	A Five Immune-Related lncRNA Signature as a Prognostic Target for Glioblastoma. <b>2021</b> , 8, 632837	7
808	Fibrinogen in the glioblastoma microenvironment contributes to the invasiveness of brain tumor-initiating cells. <b>2021</b> , 31, e12947	4
807	The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. <b>2021</b> , 11, 6067	7
806	Residual Disease in Glioma Recurrence: A Dangerous Liaison with Senescence. <b>2021</b> , 13,	3
805	Clinical Potential of Nerve Input to Tumors: A Bioelectricity Perspective. <b>2021</b> , 3, 14-26	1
804	Cellular Internalization and Inhibition Capacity of New Anti-Glioma Peptide Conjugates: Physicochemical Characterization and Evaluation on Various Monolayer- and 3D-Spheroid-Based Platforms. <b>2021</b> , 64, 2982-3005	5
803	Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma. <b>2021</b> , 6, 35-48	2
802	Energy Metabolism in Wild-Type and -Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?. <b>2021</b> , 10,	6

801	A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. <b>2021</b> , 13,	38
800	Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies. <b>2021</b> , 22,	0
799	MR-Guided Radiotherapy for Brain and Spine Tumors. <b>2021</b> , 11, 626100	7
798	A review of Tumor Treating Fields and their future implication in treatment of platinum resistant ovarian cancer. <b>2021</b> , 12,	
797	Rapid Progressive Glioblastoma despite Radiation in a Patient with Myelodysplastic Syndrome. <b>2021</b> , 14, 424-429	
796	Long non-coding RNA SUMO1P3 promotes tumour progression by regulating cell proliferation and invasion in glioma. <b>2021</b> , 21, 491	3
795	The Tumor Suppressor /ATIP1 Modulates Tumor Promotion in Glioma: Association with Epigenetics and DNA Repair. <b>2021</b> , 13,	4
794	Hyperpolarized C-glucose magnetic resonance highlights reduced aerobic glycolysis in vivo in infiltrative glioblastoma. <b>2021</b> , 11, 5771	4
793	Proteogenomics of glioblastoma associates molecular patterns with survival. <b>2021</b> , 34, 108787	6
792	Current FDA-Approved Therapies for High-Grade Malignant Gliomas. <b>2021</b> , 9,	26
791	Adjuvant therapeutic potential of moderate hypothermia for glioblastoma. <b>2021</b> , 152, 467-482	1
790	Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. <b>2021</b> , 85, 115-121	2
789	Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial. <b>2021</b> , 152, 501-514	14
788	Tumor-Treating Fields Therapy for Pediatric Brain Tumors. <b>2021</b> , 13, 151-165	0
787	Therapeutic Delivery to Central Nervous System. <b>2021</b> , 32, 291-303	5
786	Drug target ranking for glioblastoma multiforme. <b>2021</b> , 3, 7	1
785	Diagnosis and Management of Glioblastoma: A Comprehensive Perspective. <b>2021</b> , 11,	7
784	Topography of transcriptionally active chromatin in glioblastoma. <b>2021</b> , 7,	4

783	Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review. <b>2021</b> , 11,	3
782	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. <b>2021</b> , 23, 1885-1897	3
781	Proteogenomic and metabolomic characterization of human glioblastoma. <b>2021</b> , 39, 509-528.e20	71
780	Frontiers in the treatment of glioblastoma: Past, present and emerging. <b>2021</b> , 171, 108-138	29
779	Endoplasmic Reticulum Stress Contributes to Gefitinib-Induced Apoptosis in Glioma. <b>2021</b> , 22,	3
778	Partial response to Chinese patent medicine Kangliu pill for adult glioblastoma: A case report and review of the literature. <b>2021</b> , 9, 2845-2853	0
777	Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences. <b>2021</b> , 13,	8
776	Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis. <b>2021</b> , 8, 426-440	3
775	Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma. <b>2021</b> , 86, 202-210	4
774	An Alternative Pipeline for Glioblastoma Therapeutics: A Systematic Review of Drug Repurposing in Glioblastoma. <b>2021</b> , 13,	2
773	Immunomodulatory Effect of Microglia-Released Cytokines in Gliomas. <b>2021</b> , 11,	7
772	Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. <b>2021</b> , 22,	15
771	A review on tumor treating fields, a novel modality in cancer treatment. <b>2021</b> , 53, S17-S18	
770	Causes of drug resistance and glioblastoma relapses. <b>2021</b> , 11, 101-108	
769	MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44. <b>2021</b> , 11, 9219	5
768	Ultrasound-responsive nutlin-loaded nanoparticles for combined chemotherapy and piezoelectric treatment of glioblastoma cells. <b>2021</b> ,	9
767	An Overview of High-grade Glioma: Current and Emerging Treatment Approaches. <b>2021</b> , 17, 35-48	
766	Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features. <b>2021</b> , 11, 627325	5

765	De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. <b>2021</b> , 144, 1230-1246	4
764	An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5. <b>2021</b> , 22,	3
763	Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer. <b>2021</b> , 14, 2397-2415	2
762	PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma. <b>2021</b> , 153, 153-160	9
761	Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and F-FMISO PET. <b>2021</b> , 11, 7632	3
760	Integration of Molecular Analysis, Cutting-edge Mouse Genetic Models and Proton Therapy to Improve Outcomes for Glioma Patients. 79-96	0
759	Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of -Mutant Glioblastoma: An 80-Month Follow-Up Case Report. <b>2021</b> , 8, 682243	5
758	Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database. <b>2021</b> , 89, 196-203	0
757	Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives. <b>2021</b> , 97, 218-230	3
756	Immunotherapy and radiation for high-grade glioma: a narrative review.. <b>2021</b> , 10, 2537-2570	2
755	Permeabilizing Cell Membranes with Electric Fields. <b>2021</b> , 13,	4
754	Tumor Treating Fields : Additional Mechanisms and Additional Applications. <b>2021</b> , 64, 469-471	0
753	Elevated fibroblast growth factor-inducible 14 expression transforms proneural-like gliomas into more aggressive and lethal brain cancer. <b>2021</b> , 69, 2199-2214	0
752	Thymidine decreases the DNA damage and apoptosis caused by tumor-treating fields in cancer cell lines. <b>2021</b> , 43, 995-1001	0
751	Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma. <b>2021</b> , 11, 671044	2
750	Molecular Markers of Gliomas to Predict Treatment and Prognosis: Current State and Future Directions. 171-186	
749	Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. <b>2021</b> , 13,	10
748	Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma. <b>2021</b> , 11, 632663	0

747	Therapeutic Potential of Curcumin for the Treatment of Malignant Gliomas. 139-150	1
746	A Physical Perspective on Oncology Research: The Critically Emerging Role of Physical Science in the Fight Against Brain Cancer. <b>2021</b> , 1, 213-221	
745	Dandy's hemispherectomies: historical vignette. <b>2021</b> , 1-7	1
744	Immunotherapy for Glioblastoma: Current Progress and Challenges. <b>2021</b> , 12, 676301	11
743	World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology. <b>2021</b> , 11, 659800	2
742	Feasibility and clinical usefulness of modelling glioblastoma migration in adjuvant radiotherapy. <b>2021</b> ,	0
741	Potential Use of Nitrogen-Doped Carbon Nanotube Sponges as Payload Carriers Against Malignant Glioma. <b>2021</b> , 11,	3
740	Emerging Roles of Wild-type and Mutant IDH1 in Growth, Metabolism and Therapeutics of Glioma. 61-78	1
739	Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. <b>2021</b> , 10,	5
738	BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma. <b>2021</b> , 23, 1680-1692	5
737	Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study. <b>2021</b> , 12, 632547	1
736	Gene Therapy for the Treatment of Malignant Glioma. <b>2021</b> , 1, 189-202	1
735	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. <b>2021</b> , 11, 679702	3
734	A Prospective Validation Study of the First 3D Digital Exoscope for Visualization of 5-ALA-Induced Fluorescence in High-Grade Gliomas. <b>2021</b> , 149, e498-e503	4
733	The relationship between PLOD1 expression level and glioma prognosis investigated using public databases. <b>2021</b> , 9, e11422	2
732	A Correlation Between Electric Fields That Target the Cell Membrane Potential and Dividing HeLa Cancer Cell Growth Inhibition. <b>2021</b> , 68, 1951-1956	3
731	Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression. <b>2021</b> , 12, 3895	2
730	Viral Control of Glioblastoma. <b>2021</b> , 13,	2

729	Purine synthesis as a target for radiation resistance in molecular glioblastoma. <b>2021</b> , 425, 117439	
728	Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. <b>2021</b> , 9,	7
727	Stem cells for the treatment of glioblastoma: a 20-year perspective. <b>2021</b> , 10, CNS73	1
726	Safety of Tumor Treating Fields (TTFields) Applied to the Torso. <b>2021</b> , 11, 670809	6
725	Advances in Chemokine Signaling Pathways as Therapeutic Targets in Glioblastoma. <b>2021</b> , 13,	15
724	Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?. <b>2021</b> , 153, 537-545	1
723	The current and future aspects of glioblastoma: Immunotherapy a new hope?. <b>2021</b> , 54, 5120-5142	3
722	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <b>2021</b> , 26, 865-878	7
721	Aging- and Tumor-Mediated Increase in CD8CD28 T Cells Might Impose a Strong Barrier to Success of Immunotherapy in Glioblastoma. <b>2021</b> , 5, 395-409	2
720	The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors. <b>2021</b> , 11, 654921	2
719	Hitting more birds with one stone: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma.	
718	SH3BGRL3, transcribed by STAT3, facilitates glioblastoma tumorigenesis by activating STAT3 signaling. <b>2021</b> , 556, 114-120	2
717	Advances in the management of glioblastoma. <b>2021</b> , 92, 1103-1111	4
716	Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme. <b>2021</b> , 10, 5019-5030	2
715	Current Development of Glioblastoma Therapeutic Agents. <b>2021</b> , 20, 1521-1532	2
714	A Comparative Retrospective Study of Immunotherapy RANO Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. <b>2021</b> , 11, 679331	1
713	Palliative Care Service Utilization and Advance Care Planning for Adult Glioblastoma Patients: A Systematic Review. <b>2021</b> , 13,	2
712	DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies. <b>2021</b> ,	1



711	Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome. <b>2021</b> , 16, e0252614	2
710	Argyris F Treatment-Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma. <b>2021</b> , 4, 2100078	0
709	Therapie maligner Gliome   Update 2021. <b>2021</b> , 4, 345-355	
708	Glioblastoma: Emerging Treatments and Novel Trial Designs. <b>2021</b> , 13,	5
707	Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas. <b>2021</b> , 22,	4
706	Glioblastoma Multiforme-A Look at the Past and a Glance at the Future. <b>2021</b> , 13,	4
705	Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?. <b>2021</b> , 22, 1983-1994	0
704	Dexamethasone Treatment Limits Efficacy of Radiation, but Does Not Interfere With Glioma Cell Death Induced by Tumor Treating Fields. <b>2021</b> , 11, 715031	1
703	Electrotherapies for Glioblastoma. <b>2021</b> , 8, e2100978	5
702	58/w mit zunehmender psychomotorischer Verlangsamung und Zephalgien. <b>2021</b> , 27, 79-84	
701	Liposomal Extravasation and Accumulation in Tumors as Studied by Fluorescence Microscopy and Imaging Depend on the Fluorescent Label. <b>2021</b> ,	3
700	The application of feature engineering in establishing a rapid and robust model for identifying patients with glioma. <b>2021</b> , 1	0
699	MicroRNA-138 Increases Chemo-Sensitivity of Glioblastoma through Downregulation of Survivin. <b>2021</b> , 9,	0
698	Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice.	
697	Tumor Treating Fields for Ovarian Carcinoma: A Modeling Study. <b>2021</b> , 6, 100716	1
696	RECQ1 Promotes Stress Resistance and DNA Replication Progression Through PARP1 Signaling Pathway in Glioblastoma. <b>2021</b> , 9, 714868	1
695	Immunotherapy in Glioblastoma: A Clinical Perspective. <b>2021</b> , 13,	3
694	Imaging-Genomics in Glioblastoma: Combining Molecular and Imaging Signatures. <b>2021</b> , 11, 699265	4

693	Combination chemoradiotherapy with temozolomide, vincristine, and interferon- $\gamma$ might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma. <b>2021</b> , 21, 867	1
692	PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma-initiating cell properties via DNA methyltransferase 3A. <b>2021</b> ,	1
691	Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on C-methionine PET: a retrospective, single-center study. <b>2021</b> , 11, 14554	0
690	Knockdown Sensitizes Glioma Cells to Radiation Through Impairing Homologous Recombination Via Targeting. <b>2021</b> , 40, 895-905	2
689	Sex-Specific Differences in Glioblastoma. <b>2021</b> , 10,	11
688	Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device. <b>2021</b> , 11, 708017	4
687	Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide. <b>2021</b> , 11, 14161	1
686	Combining MRI and Histologic Imaging Features for Predicting Overall Survival in Patients with Glioma. <b>2021</b> , 3, e200108	1
685	Piezoelectric Nanomaterials Activated by Ultrasound: The Pathway from Discovery to Future Clinical Adoption. <b>2021</b> ,	21
684	GRGDS-conjugated and curcumin-loaded magnetic polymeric nanoparticles for the hyperthermia treatment of glioblastoma cells. <b>2021</b> , 622, 126648	7
683	Roles of Neutrophils in Glioma and Brain Metastases. <b>2021</b> , 12, 701383	5
682	Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. <b>2021</b> , 13,	1
681	Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice. <b>2021</b> , 9, 133	1
680	Emerging Nano-Carrier Strategies for Brain Tumor Drug Delivery and Considerations for Clinical Translation. <b>2021</b> , 13,	4
679	Age is associated with unfavorable neuropathological and radiological features and poor outcome in patients with WHO grade 2 and 3 gliomas. <b>2021</b> , 11, 17380	1
678	Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy. <b>2021</b> , 22,	0
677	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. <b>2021</b> , 9, e04604	0
676	Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma. <b>2021</b> , 2021, 2191709	2

675	Expression Analysis of $\beta$ Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma. <b>2021</b> , 14,	1
674	WNT Signaling as a Therapeutic Target for Glioblastoma. <b>2021</b> , 22,	3
673	Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. <b>2021</b> , 11, 703764	3
672	Multi-parametric MRI (mpMRI) for treatment response assessment of radiation therapy. <b>2021</b> ,	0
671	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. <b>2021</b> , 22, 1103-1114	26
670	Genome scale CRISPR Cas9a knockout screen reveals genes that controls glioblastoma susceptibility to the alkylating agent temozolomide.	
669	Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report. <b>2021</b> , 49, 3000605211036847	0
668	Personalised, image-guided, noninvasive brain stimulation in gliomas: Rationale, challenges and opportunities. <b>2021</b> , 70, 103514	0
667	Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields. <b>2021</b> , 147, 3577-3589	2
666	Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients. <b>2021</b> , 12, 722479	1
665	Circulating Biomarkers in Glioblastoma: Ready for Prime Time?. <b>2021</b> , 27, 404-409	2
664	Changes of healthy brain tissue after salvage radiotherapy of glioblastoma.. <b>2021</b> , 3, vdab139	
663	Prognostic and Predictive Biomarkers in Gliomas. <b>2021</b> , 22,	13
662	Lack of benefit of temozolomide for MGMT methylated patients with high vascular glioblastoma: a confirmatory study.	
661	Current Immunotherapeutic Strategies for the Treatment of Glioblastoma. <b>2021</b> , 13,	4
660	Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells. <b>2021</b> , 171, 105764	5
659	The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. <b>2021</b> , 12, 885	2
658	Enhanced Microglia Activation and Glioma Tumor Progression by Inflammagen Priming in Mice with Tumor Necrosis Factor Receptor Type 2 Deficiency. <b>2021</b> , 11,	1

657	The Challenges and Future of Immunotherapy for Gliomas. <b>2021</b> , 27, 371-378	1
656	Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma. <b>2021</b> , 22,	1
655	Viral targeting of glioblastoma stem cells with patient-specific genetic and post-translational p53 deregulations. <b>2021</b> , 36, 109673	0
654	Clinical Targeting of Altered Metabolism in High-Grade Glioma. <b>2021</b> , 27, 386-394	0
653	Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics. <b>2021</b> , 40, 6059-6070	3
652	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <b>2021</b> ,	4
651	Mechanisms involved in the anti-tumor effects of Toosendanin in glioma cells. <b>2021</b> , 21, 492	1
650	Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy. <b>2021</b> , 12, 746168	2
649	Broad immunophenotyping of the murine brain tumor microenvironment. <b>2021</b> , 499, 113158	0
648	Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study. <b>2021</b> , 10, CNS76	2
647	Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. <b>2021</b> , 11, 671972	4
646	Progress and prospect in tumor treating fields treatment of glioblastoma. <b>2021</b> , 141, 111810	1
645	Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial. <b>2021</b> , 21, 1010	2
644	Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes. <b>2021</b> , 22,	2
643	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <b>2021</b> ,	4
642	Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. <b>2021</b> , 379, 343-357	0
641	Immunomodulatory Effects of Tryptophan Metabolism in the Glioma Tumor Microenvironment. <b>2021</b> , 12, 730289	2
640	Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. <b>2021</b> , 111, 371-384	3

639	Development of bozepinib-loaded nanocapsules for nose-to-brain delivery: preclinical evaluation in glioblastoma. <b>2021</b> , 16, 2095-2115	1
638	Biomaterials-based bioengineering strategies for bioelectronic medicine. <b>2021</b> , 146, 100630	4
637	Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models. <b>2021</b> , 160, 99-110	3
636	Current treatment of brain tumours. <b>2021</b> , 22, 206-211	0
635	Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy. <b>2022</b> , 127-151	
634	Chemokine receptor antagonists as immunotherapy agents and adjuncts for glioblastoma. <b>2022</b> , 153-161	
633	Immune checkpoint blockade therapy in high-grade glioma. <b>2022</b> , 91-108	
632	Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells. <b>2021</b> , 39, 536-550	3
631	Approach to the high-grade glioma patient. <b>2021</b> , 153-171	
630	Photothermal Therapy for the Treatment of Glioblastoma: Potential and Preclinical Challenges. <b>2020</b> , 10, 610356	7
629	Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. <b>2021</b> , 6,	4
628	Newly discovered neuron-to-glioma communication: new noninvasive therapeutic opportunities on the horizon?. <b>2021</b> , 3, vdab018	1
627	Beyond the Warburg Effect: Oxidative and Glycolytic Phenotypes Coexist within the Metabolic Heterogeneity of Glioblastoma. <b>2021</b> , 10,	16
626	A systematic review of multifocal and multicentric glioblastoma. <b>2021</b> , 83, 71-76	8
625	A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care. <b>2021</b> , 151, 103-112	5
624	Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database. <b>2021</b> , 3, vdab040	1
623	Literatur. <b>2021</b> , 179-184	
622	New Glioma Molecular Classification for Precise Therapeutic Decision Based on Spatially-Resolved Proteogenomics Guided by MALDI-MSI and Clinical Data Integration.	

621	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. <b>2021</b> , 6,	14
620	Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. <b>2021</b> , 3, vdab099	3
619	The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells. <b>2020</b> , 10, 603738	1
618	MRI Brain Tumor Segmentation Using 3D U-Net with Dense Encoder Blocks and Residual Decoder Blocks. <b>2021</b> , 128, 427-445	0
617	Advances in Research of Adult Gliomas. <b>2021</b> , 22,	8
616	Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy. <b>2021</b> , 587-634	1
615	Estimation of TTFIELDS Intensity and Anisotropy with Singular Value Decomposition: A New and Comprehensive Method for Dosimetry of TTFIELDS. <b>2019</b> , 173-193	4
614	Investigating the Connection Between Tumor-Treating Fields Distribution in the Brain and Glioblastoma Patient Outcomes. A Simulation-Based Study Utilizing a Novel Model Creation Technique. <b>2019</b> , 139-154	3
613	Primary Central Nervous System Tumors. <b>2020</b> , 295-325	1
612	Tumor-Treating Fields at EMBC 2019: A Roadmap to Developing a Framework for TTFIELDS Dosimetry and Treatment Planning. <b>2021</b> , 3-17	1
611	Improving Tumor-Treating Fields with Skull Remodeling Surgery, Surgery Planning, and Treatment Evaluation with Finite Element Methods. <b>2021</b> , 63-77	1
610	3-Bromofascaplysin is a prospective chemical compound for developing new chemotherapy agents in glioblastoma treatment. <b>2020</b> , 151, 325-343	2
609	Nanomedicine for Spontaneous Brain Tumors: A Companion Clinical Trial. <b>2019</b> , 13, 2858-2869	30
608	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <b>2020</b> , 22, 601-612	12
607	Proteogenomics of glioblastoma associates molecular patterns with survival.	1
606	Overall patient survival of glioblastoma associated to molecular markers: a pan-proteomic prospective study.	2
605	Adult Gliomas. <b>2020</b> , 26, 1452-1475	5
604	The Longitudinal Imaging Tracker (BRICS-LIT):A Cloud Platform for Monitoring Treatment Response in Glioblastoma Patients. <b>2020</b> , 6, 93-100	5

603	Tumour treating fields in a combinational therapeutic approach. <b>2018</b> , 9, 36631-36644	18
602	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. <b>2020</b> , 11, 3489-3501	13
601	Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. <b>2021</b> , 4, 17-43	15
600	Expression of P-gp in Glioblastoma: What we can Learn from Brain Development. <b>2020</b> , 26, 1428-1437	9
599	Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells. <b>2020</b> , 20, 734-750	3
598	GammaTile: Surgically targeted radiation therapy for glioblastomas. <b>2020</b> , 16, 2445-2455	14
597	The algorithms of adjuvant therapy in gliomas and their effect on survival. <b>2019</b> , 63, 179-186	4
596	Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?. <b>2019</b> , 132, 1667-1672	5
595	Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients. <b>2020</b> , 49, E11	3
594	The Value of Tumor Treating Fields in Glioblastoma. <b>2020</b> , 63, 681-688	6
593	Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide. <b>2020</b> , 12,	7
592	Nanomedicine: A Useful Tool against Glioma Stem Cells. <b>2020</b> , 13,	8
591	Myeloid Cells in Glioblastoma Microenvironment. <b>2020</b> , 10,	25
590	Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields. <b>2020</b> , 19, 557-561	3
589	PI3K/mTORC1/2 inhibitor PQR309 inhibits proliferation and induces apoptosis in human glioblastoma cells. <b>2020</b> , 43, 773-782	3
588	Management of glioma patients during the coronavirus disease 2019 pandemic. <b>2020</b> , 3, 31	1
587	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <b>2020</b> , 18, 1537-1570	83
586	Multiple subtentorial metastasis in diffuse midline glioma receiving tumor treating fields: a case report and literature review. <b>2021</b> , 9, 1604	1

585	Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With V600E-Mutated Gliomas. <b>2021</b> , 28, 10732748211040013	2
584	Preoperative Apparent Diffusion Coefficient of Peritumoral Lesion Associate with Recurrence in Patients with Glioblastoma. <b>2021</b> , 62,	
583	Targeting Accuracy Considerations for Simultaneous Tumor Treating Fields Antimitotic Therapy During Robotic Hypofractionated Radiation Therapy. <b>2021</b> , 20, 15330338211039135	
582	Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation. <b>2021</b> , 266, 195-209	0
581	Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. <b>2021</b> , 112, 5020-5033	3
580	Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets. <b>2021</b> , 11, 20338	0
579	Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. <b>2022</b> , 36, 269-282	0
578	Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. <b>2021</b> , 218,	2
577	Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients. <b>2021</b> , 21, 1108	1
576	ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppression. <b>2021</b> , 11, 20839	2
575	A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma. <b>2021</b> , 3, vdab156	0
574	New Approaches to Glioblastoma. <b>2021</b> ,	0
573	Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial. <b>2021</b> , 155, 117-124	0
572	Electrolyte and renal disorders in patients with newly diagnosed glioblastoma. <b>2021</b> , 17, 4711-4719	0
571	Emerging Epigenetic Therapies for Brain Tumors. <b>2021</b> , 1	4
570	Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma. <b>2021</b> , 13,	0
569	Update on Radiation Therapy for Central Nervous System Tumors. <b>2022</b> , 36, 77-93	0
568	Upregulated Expression of Cancer-Derived Immunoglobulin G Is Associated With Progression in Glioma. <b>2021</b> , 11, 758856	0



- 567 Targeting gene fusions in glioma. **2021**, 34, 840-847 0
- 566 Three-dimensional culture models to study glioblastoma - current trends and future perspectives. **2021**, 61, 91-97 1
- 565 In Reply. **2018**, 115, 674 1
- 564 The Study Was Subject to Considerable Bias. **2018**, 115, 674
- 563 Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma.
- 562 Landmark Trials in Selected Central Nervous System Tumors. **2019**, 273-302
- 561 Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. **2019**, e.1-e.39
- 560 Central Nervous System Cancers. **2019**, 83-131 0
- 559 Glioma Treatment focusing on Brain Function. **2019**, 28, 686-698
- 558 Gliome. **2019**, 1-14
- 557 Insights from Computer Modeling: Analysis of Physical Characteristics of Glioblastoma in Patients Treated with Tumor-Treating Fields. **2019**, 155-161 0
- 556 Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?. **2019**, 8, 4-6
- 555 Interaction between DNA damage response, translation and apoptosome determines cancer susceptibility to TOP2 poisons. 1
- 554 Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cells.
- 553 CD8+ T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas.
- 552 Exponential Growth of Glioblastoma In Vivo Driven by Rapidly Dividing and Outwardly Migrating Cancer Stem Cells.
- 551 JAM-A functions as a female microglial tumor suppressor in glioblastoma.
- 550 Indications and Limitations of Conventional Imaging in Current Clinical Practice in the Context of Standard Therapy. **2020**, 1-15 0

549	Gliome. <b>2020</b> , 1-14	
548	Role of Whole-Brain Radiotherapy. <b>2020</b> , 281-298	
547	Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients. <b>2020</b> , 39, 444-451	0
546	Neural Stem Cells Secreting Bispecific T Cell Engager to Induce Selective Anti-Glioma Activity.	
545	A Thermal Study of Tumor-Treating Fields for Glioblastoma Therapy. <b>2021</b> , 37-62	2
544	Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome.	1
543	Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study. <b>2021</b> , 27, 1587-1604	3
542	Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated. <b>2021</b> , 13,	1
541	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. <b>2022</b> , 36, 113-132	1
540	Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. <b>2021</b> , 11, 770561	5
539	Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies. <b>2021</b> , 179, 113999	6
538	Targeting Brain Tumors with Mesenchymal Stem Cells in the Experimental Model of the Orthotopic Glioblastoma in Rats. <b>2021</b> , 9,	2
537	Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. <b>2021</b> , 12, 770390	6
536	Untying the Gordian Knot : Why Glioblastomas are Still Incurable, and How Can We overcome the Hurdles. <b>2020</b> , 29, 198-203	
535	Current Status of Adjuvant Therapy for Glioblastoma and Potential Novel Therapies. <b>2020</b> , 29, 188-197	
534	Neuroonkologie. <b>2020</b> , 257-271	
533	A Method for Tumor Treating Fields Fast Estimation. <b>2020</b> , 60-67	
532	Cognitive Rehabilitation in Patients with Non-Central Nervous System Cancers and Brain Tumors. <b>2020</b> , 221-254	0

531 Chemotherapy for Brain Tumors. **2021**, 357-383

530 Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastoma.

529 Local Administration of Therapies and Drug Delivery Strategies for the Treatment of Gliomas. **2021**, 385-394

528 Gliome des Erwachsenenalters. **2021**, 1-12

527 Elektrische Wechselfelder keine Therapieoption bei Glioblastom. **2021**, 24, 48-52

526 Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma. **2021**, 3, vdaa171

1

525 Emerging Meningioma Therapies II: Immunotherapies, Novel Radiotherapy Techniques, and Other Experimental Approaches. **2020**, 227-238

524 LITT Treatment of High-Grade Gliomas. **2020**, 65-73

523 Gliome. **2020**, 997-1010

522 Advancement of clinical therapeutic research on glioma: A narrative review. **2020**, 3, 119

1

521 Current Status of Glioblastoma Treatment. **2020**, 10, 2875-2882

520 Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner.

1

519 A Multifunctional AIE Nanoprobe as a Drug Delivery Bioimaging and Cancer Treatment System. **2021**, 9, 766470

0

518 Advances in Pancreatic Ductal Adenocarcinoma Treatment. **2021**, 13,

4

517 PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFB pathway. **2021**, 7, eabh2148

0

516 Neues zur Diagnostik und Therapie von Gliomen. **2020**, 10, 199-214

515 Feasibility of Treating High Grade Gliomas in Children with Tumor-Treating Fields: A Case Series. **2020**, 12, e10804

0

514 LNX1 Modulates Notch1 Signaling to Promote Expansion of the Glioma Stem Cell Population During Temozolomide Therapy in Glioblastoma.

513	Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients. <b>2021</b> , 8, 148-159	0
512	The role of extracellular vesicles in the diagnosis of glioblastoma progression. <b>2020</b> , 7, 8-18	
511	Newly Diagnosed Glioblastoma: A Review on Clinical Management. <b>2019</b> , 33, 91-100	35
510	Organoid models of glioblastoma: advances, applications and challenges. <b>2020</b> , 10, 2242-2257	8
509	Tumor-treating fields (TTFields)-based cocktail therapy: a novel blueprint for glioblastoma treatment. <b>2021</b> , 11, 1069-1086	
508	Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring. <b>2021</b> , 13, 4489-4499	2
507	Treating solid tumors using tumor treating fields: an overview of the theory and practices. <b>2022</b> , 169-233	0
506	Glioma invasion along white matter tracts: A dilemma for neurosurgeons. <b>2021</b> , 526, 103-111	3
505	Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma. <b>2021</b> , 11, 22057	
504	Characterizing the Genomic Profile in High-Grade Gliomas: From Tumor Core to Peritumoral Brain Zone, Passing through Glioma-Derived Tumorspheres. <b>2021</b> , 10,	2
503	Glioma cells remotely promote erythropoiesis as a self-expanding strategy of cancer stem cells. <b>2021</b> ,	1
502	Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma. <b>2021</b> , 22,	4
501	Rapid Interval Recurrence of Glioblastoma Following Gross Total Resection: A Possible Indication for GammaTile(R) Brachytherapy.. <b>2021</b> , 13, e19496	0
500	In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma.. <b>2021</b> , 14,	3
499	Surgical Outcomes of Novel Collagen Tile Cesium Brachytherapy for Recurrent Intracranial Tumors at a Tertiary Referral Center.. <b>2021</b> , 13, e19777	0
498	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.. <b>2021</b> , 2, 1372-1386	3
497	Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?. <b>2021</b> , 3, 791596	2
496	Glioma Imaging by O-(2-18F-Fluoroethyl)-L-Tyrosine PET and Diffusion-Weighted MRI and Correlation With Molecular Phenotypes, Validated by PET/MR-Guided Biopsies.. <b>2021</b> , 11, 743655	0

495	Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model.. <b>2021</b> , 9,	3
494	Temporal Trends in Glioblastoma Survival: Progress then Plateau. <b>2021</b> ,	1
493	Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates. <b>2021</b> , 168, 103535	0
492	Microglia-Derived Olfactomedin-like 3 Promotes Pro-Tumorigenic Microglial Function and Malignant Features of Glioma Cells. <b>2021</b> , 22,	0
491	Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma.. <b>2021</b> , 11, 772261	0
490	Shape matters: morphological metrics of glioblastoma imaging abnormalities as biomarkers of prognosis. <b>2021</b> , 11, 23202	3
489	A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma. <b>2021</b> ,	1
488	Tumor Treating Fields Suppression of Ciliogenesis Enhances Temozolomide Toxicity.	
487	TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas.. <b>2022</b> ,	1
486	Neuro-oncology and supportive care: the role of the neurologist.. <b>2022</b> , 1	1
485	Targeting immunoliposomes to EGFR-positive glioblastoma.. <b>2022</b> , 7, 100365	4
484	Survival benefit of concomitant chemoradiation in adult supratentorial primary glioblastoma. A propensity score weighted population-based analysis. <b>2020</b> ,	
483	Distinct survival and clinical profile of infantile glioblastoma: insights from a national database. <b>2021</b> , 38, 85	0
482	Our Experience in using the Novo-TTF 100A System for the Treatment of Glioblastoma. <b>2021</b> , 80, 253-257	
481	A computational study of the relation between the power density in the tumor and the maximum temperature in the scalp during Tumor Treating Fields (TTFields) therapy. <b>2021</b> , 2021, 4192-4195	0
480	Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.. <b>2021</b> , 156, 407	
479	Sex Differences in Glioblastoma-Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999-2018.. <b>2022</b> , 11,	0
478	Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma.. <b>2021</b> , 11, 812916	3

477	A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma.. <b>2022</b> , 4, vdac006	3
476	Deep Learning Characterization of Brain Tumours With Diffusion Weighted Imaging.	
475	Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma.	
474	Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma.. <b>2022</b> , 4, vdac002	0
473	CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.. <b>2022</b> , 10,	4
472	Preoperative Stereotactic Radiosurgery for Glioblastoma.. <b>2022</b> , 11,	0
471	Genome-scale CRISPR Cas9a knockout screen reveals genes that control glioblastoma susceptibility to the alkylating agent temozolomide. <b>2022</b> , 15, 88-93	
470	A Randomized Feasibility Study Evaluating Temozolomide Circadian Medicine in Patients with Glioma.	1
469	Ensembles of Convolutional Neural Networks for Survival Time Estimation of High-Grade Glioma Patients from Multimodal MRI.. <b>2022</b> , 12,	1
468	Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation.. <b>2022</b> , 13, 354-363	1
467	Neuroimmunomodulatory Properties of Flavonoids and Derivates: A Potential Action as Adjuvants for the Treatment of Glioblastoma.. <b>2022</b> , 14,	1
466	Brain tumor craniotomy outcomes for dual-eligible medicare and medicaid patients: a 10-year nationwide analysis.. <b>2022</b> , 156, 387	0
465	Multidisciplinary Treatment for Glioblastoma. <b>2022</b> , 31, 11-19	
464	Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment.. <b>2022</b> , 14,	1
463	Combined Fluorescence-Guided Resection and Intracavitary Thermotherapy with Superparamagnetic Iron-Oxide Nanoparticles for Recurrent High-Grade Glioma: Case Series with Emphasis on Complication Management.. <b>2022</b> , 14,	
462	Endoplasmic Reticulum Stress Contributed to Dipyrindamole-Induced Impaired Autophagic Flux and Glioma Apoptosis.. <b>2022</b> , 23,	0
461	Prognostic and Predictive Factors in Elderly Patients With Glioblastoma: A Single-Center Retrospective Study.. <b>2021</b> , 13, 777962	0
460	Introductory Chapter: The Current State of the Treatment of CNS Malignancies.	

459	Would they do it again? Final treatment decisions in malignant brain tumour patients-a caregiver's perspective.. <b>2022</b> , 30, 3985	0
458	Impact of General Factors on Glioma Immunotherapy.. <b>2022</b> , 18, 3-13	0
457	The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.. <b>2022</b> , 156, 257	1
456	Glutamic acid and total creatine as predictive markers for epilepsy in glioblastoma by using magnetic resonance spectroscopy prior to surgery.. <b>2022</b> ,	
455	Application of the Taguchi method to explore a robust condition of tumor-treating field treatment.. <b>2022</b> , 17, e0262133	
454	Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma.. <b>2022</b> , 1-10	1
453	Mechanical Properties in the Glioma Microenvironment: Emerging Insights and Theranostic Opportunities.. <b>2021</b> , 11, 805628	0
452	Human glioblastoma cell motility depends on the activity of the cysteine metabolism enzyme 3-Mercaptopyruvate sulfurtransferase.	
451	Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma.. <b>2022</b> ,	0
450	Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives.. <b>2022</b> , 14,	5
449	Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors.. <b>2022</b> , 14,	2
448	Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.. <b>2022</b> , 23,	2
447	Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma.. <b>2022</b> , 24, 522-534	3
446	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.. <b>2021</b> , JCO21020360	
445	Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy.. <b>2022</b> , 230, 114118	2
444	Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma.. <b>2022</b> , 157, 137	0
443	Non-coding RNAs and glioblastoma: Insight into their roles in metastasis.. <b>2022</b> , 24, 262-287	3
442	FRAT1 promotes the angiogenic properties of human glioblastoma cells via VEGFA.. <b>2022</b> , 25,	1

441	Genome-Wide Expression and Anti-Proliferative Effects of Electric Field Therapy on Pediatric and Adult Brain Tumors.. <b>2022</b> , 23,	0
440	Glioma targeted therapy: insight into future of molecular approaches.. <b>2022</b> , 21, 39	26
439	Clinical Significance and Immune Landscape of a Pyroptosis-Derived LncRNA Signature for Glioblastoma.. <b>2022</b> , 10, 805291	1
438	Newly Diagnosed Glioblastoma in Elderly Patients.. <b>2022</b> , 24, 325	
437	Upregulation of Cathepsin X in Glioblastoma: Interplay with ßEnolase and the Effects of Selective Cathepsin X Inhibitors.. <b>2022</b> , 23,	1
436	Managing Central Nervous System Tumors During Pregnancy.. <b>2022</b> , 28, 122-146	0
435	A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitronone-based OKN-007.. <b>2021</b> ,	1
434	HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation.. <b>2022</b> , 19, 151-162	0
433	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.. <b>2022</b> , 4, vdac025	2
432	Quality of Life and Brain Cancer. <b>2022</b> , 385-408	
431	Application of the anthraquinone drug rhein as an axial ligand in bifunctional Pt(IV) complexes to obtain antiproliferative agents against human glioblastoma cells.. <b>2022</b> ,	0
430	Tracking glioblastoma progression after initial resection with minimal reaction-diffusion models. <b>2022</b> , 19, 5446-5481	
429	Targeting the Replication Stress of Glioblastoma. <b>2022</b> , 12, 42-51	
428	Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma.. <b>2022</b> , 10,	2
427	Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma.. <b>2022</b> ,	4
426	CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.. <b>2022</b> , 13, 817296	4
425	Tumour treating fields in glioblastoma: is the treatment tolerable, effective, and practical in UK patients?. <b>2022</b> , 1-7	
424	Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-Î through PD-L1 and IDO1.	0



423	Complete and Incomplete Resection for Progressive Glioblastoma Prolongs Post-Progression Survival.. <b>2022</b> , 12, 755430	0
422	Methylome analysis for prediction of long and short-term survival in glioblastoma patients from the Nordic trial.	
421	Molecular Mechanisms and Clinical Challenges of Glioma Invasion.. <b>2022</b> , 12,	1
420	Improving control of high-grade glioma by ultra-hyper-fractionated radiotherapy.. <b>2022</b> ,	1
419	HSPA6 is Correlated With the Malignant Progression and Immune Microenvironment of Gliomas.. <b>2022</b> , 10, 833938	0
418	Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.. <b>2022</b> , 1	0
417	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease.. <b>2022</b> , 12, 849993	
416	Cell Responsiveness to Physical Energies: Paving the Way to Decipher a Morphogenetic Code.. <b>2022</b> , 23,	0
415	Trends and Outcomes of Early and Late Palliative Care Consultation for Adult Patients with Glioblastoma: A SEER-Medicare Retrospective Study.	2
414	Glioblastoma with concomitant moyamoya vasculopathy in neurofibromatosis type 1: illustrative case. <b>2022</b> , 3,	
413	The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression.. <b>2022</b> , 10,	5
412	Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma.. <b>2022</b> , 8, 688-700	1
411	Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.. <b>2022</b> , 14,	0
410	Tumor Treating Fields Suppression of Ciliogenesis Enhances Temozolomide Toxicity.. <b>2022</b> , 12, 837589	0
409	An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.. <b>2022</b> , 13, 1-12	0
408	Essential Management of Pediatric Brain Tumors.. <b>2022</b> , 9,	0
407	Efficacy and safety of bevacizumab combined with other therapeutic regimens for treatment of recurrent glioblastoma: A network meta-analysis.. <b>2021</b> ,	2
406	Hypofractionation in Older Adults With Glioblastoma.. <b>2022</b> , 32, 168-171	

405	Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.. <b>2022,</b>	1
404	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <b>2022, 82, 491</b>	2
403	Glioblastoma microenvironment: The stromal interactions.. <b>2022, 232, 153813</b>	1
402	Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.. <b>2022, 1</b>	0
401	The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns.. <b>2021,</b>	3
400	Effectiveness of different treatment strategies in elderly patients with glioblastoma: an evidence map of randomised controlled trials.. <b>2022, 103645</b>	0
399	Spatiotemporal dynamics and optimal control of glioma virotherapy enhanced by MEK Inhibitors. <b>2022, 7, 100101</b>	
398	GPER Agonist G-1 Disrupts Tubulin Dynamics and Potentiates Temozolomide to Impair Glioblastoma Cell Proliferation.. <b>2021, 10,</b>	1
397	Gene Alterations Define Specific Features of a Subset of Glioblastomas.. <b>2021, 23,</b>	1
396	Tumor Treating Fields: A Comprehensive Overview of the Underlying Molecular Mechanism. <b>2021,</b>	0
395	GammaTile <sup>®</sup> brachytherapy in the treatment of recurrent glioblastomas.. <b>2022, 4, vdab185</b>	0
394	Immunotherapy against Gliomas.	
393	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <b>2022, 24, 358-383</b>	1
392	Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma.. <b>2021, 9, 1804</b>	0
391	Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy.. <b>2021,</b>	2
390	SerpinB3 drives cancer stem cell survival in glioblastoma.	
389	Role of Prophylactic Cranial Irradiation in Extensive-Stage Small Cell Lung Cancer.. <b>2021, 19, 1465-1469</b>	1
388	Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment.. <b>2021, 10,</b>	4

387	Effect of duty cycles of tumor-treating fields on glioblastoma cells and normal brain organoids.. <b>2022</b> , 60,	1
386	The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.. <b>2022</b> , 157, 177	2
385	First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis.. <b>2022</b> , 12,	0
384	Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma.. <b>2022</b> , 14,	0
383	Brain co-delivery of first-line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy. 20210274	6
382	Emerging therapies for glioblastoma: current state and future directions.. <b>2022</b> , 41, 142	7
381	Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis.. <b>2022</b> , 1	1
380	Tumor Treating Fields: killing two birds with one stone.. <b>2022</b> , 132,	2
379	Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).. <b>2022</b> , 60,	3
378	Flap endonuclease 1 and DNA-PKcs synergistically participate in stabilizing replication fork to encounter replication stress in glioma cells.. <b>2022</b> , 41, 140	0
377	Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and Stemness, and Slows Tumor Growth .. <b>2022</b> , 12, 852940	1
376	Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.. <b>2022</b> ,	6
375	CAMK1D Inhibits Glioma Through the PI3K/AKT/mTOR Signaling Pathway.. <b>2022</b> , 12, 845036	1
374	Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data.. <b>2022</b> , 14,	0
373	Tumor cell-intrinsic HFE drives glioblastoma growth.	0
372	Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research.. <b>2022</b> ,	0
371	Data_Sheet_1.ZIP. <b>2019</b> ,	
370	Image_1.TIF. <b>2019</b> ,	

369 Image\_2.TIF. 2019,

368 Image\_3.TIF. 2019,

367 Image\_4.TIF. 2019,

366 Image\_5.TIF. 2019,

365 Table\_1.DOCX. 2019,

364 Table\_2.DOCX. 2019,

363 Table\_3.DOCX. 2019,

362 Image\_1.tif. 2018,

361 Table\_1.docx. 2018,

360 Table\_2.docx. 2018,

359 Table\_3.docx. 2018,

358 Table\_1.XLSX. 2020,

357 Image\_1.tif. 2020,

356 Image\_2.tif. 2020,

355 Image\_3.tif. 2020,

354 Table\_1.docx. 2020,

353 Table\_2.docx. 2020,

352 Table\_3.docx. 2020,

351 Table\_1.DOCX. 2020,

350 Data\_Sheet\_1.docx. 2019,

349 Table\_1.pdf. 2019,

348 Data\_Sheet\_1.PDF. 2020,

347 Data\_Sheet\_1.docx. 2019,

346 Data\_Sheet\_2.docx. 2019,

345 Image\_1.jpg. 2019,

344 Image\_2.jpg. 2019,

343 Data\_Sheet\_1.PDF. 2020,

342 Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma.. 2022, 12, 896246 2

341 Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.. 2022, 15, 437-468 1

340 Skull modulated strategies to intensify tumor treating fields on brain tumor: a finite element study.. 2022, 0

339 MEOX2 Regulates the Growth and Survival of Glioblastoma Stem Cells by Modulating Genes of the Glycolytic Pathway and Response to Hypoxia.. 2022, 14, 0

338 Clinical Trials of Oncolytic Viruses in Glioblastoma. 2022, 2, 139-158 1

337 Overall survival time prediction for glioblastoma using multimodal deep KNN.. 2022,

336 Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI).. 2022, 1 0

335 Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy.. 2022, e2105451 3

334 Long Term Survivals in Aggressive Primary Brain Malignancies Treated With an Adjuvant Ketogenic Diet.. 2022, 9, 770796 1

- 333 Safety and efficacy of irradiation boost based on 18F-FET-PET in patients with newly diagnosed glioblastoma.. **2022**, 0
- 332 Glioblastom. **2022**, 43, 239-245
- 331 Clinical Outcomes of Dose Escalated Re-Irradiation in Patients with Recurrent High Grade Glioma.
- 330 Circulating Tumor Cells and Cell-free Tumor DNA in Evaluation and Management of Gliomas. **2022**, 2, 129-138
- 329 Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma.. **2022**,
- 328 Optimal managements of elderly patients with glioblastoma.. **2022**, 0
- 327 Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.. **2022**, 30, 100801 1
- 326 Whole exome sequencing reveals the genetic heterogeneity and evolutionary history of primary gliomas and matched recurrences. **2022**, 20, 2235-2246 0
- 325 Brain and Spinal Cord Tumors. **2022**, 133-149
- 324 A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology.. **2022**, 42, 1-8 0
- 323 Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance. 2
- 322 Proliferation and apoptosis regulation by G protein-coupled estrogen receptor in glioblastoma C6 cells. **2022**, 24, 1
- 321 Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial. **2022**, 49, 101449 0
- 320 ELECTROCHEMOTHERAPY IN THE TREATMENT OF UNRESECTABLE PANCREATIC CANCER. **2022**, 40-45
- 319 Updates in IDH-Wildtype Glioblastoma. 1
- 318 The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts. 2
- 317 The Role of Myeloid Cells in GBM Immunosuppression. **2022**, 13, 0
- 316 Technical Note: Evaluation of methods for reducing edge current density under electrode arrays for tumor treating fields therapy.

- 315 Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis. 12,
- 314 Modifiers of and Disparities in Palliative and Supportive Care Timing and Utilization among Neurosurgical Patients with Malignant Central Nervous System Tumors. **2022**, 14, 2567
- 313 Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma. **2022**, 12, 0
- 312 Standard clinical approaches and emerging modalities for glioblastoma imaging.
- 311 Low-Intensity Focused Ultrasound Technique in Glioblastoma Multiforme Treatment. 12, 0
- 310 Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning. **2022**, 14, 2762 1
- 309 Management of dermatologic adverse events associated with tumour treating fields in patients with glioblastoma multiforme: A 27-case series. **2022**, 100095 0
- 308 Current and future perspectives of chimeric antigen receptors against glioblastoma.
- 307 Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: a proof-of-principle. **2022**, 2
- 306 Rapid Early Progression (REP) of glioblastoma is an independent negative prognostic factor: results from a systematic review and meta-analysis. 0
- 305 The Cost-Effectiveness Evaluation of the Intraoperative Additional Photodynamic Therapy for the Treatment of Newly Diagnosed Glioblastoma. **2022**,
- 304 Sexual Dimorphism of Human Immune System Predicts Clinical Outcomes in Glioblastoma Immunotherapy: A Systematic Review and Meta-analysis. 0
- 303 Detailed *in vitro* analyses of the impact of multimodal cancer therapy with hyperthermia and radiotherapy on the immune phenotype of human glioblastoma cells. **2022**, 39, 796-805 1
- 302 Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives. **2022**, 9, 0
- 301 Optimizing the Radiotherapy Treatment Planning Process for Glioblastoma.
- 300 Leveraging the CSF proteome toward minimally-invasive diagnostics and biological characterization of brain malignancies.
- 299 High-dose salvage re-irradiation in recurrent/progressive adult diffuse gliomas: development of a novel prognostic scoring system. **2022**, 1
- 298 The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO IV. 13, 1

297	Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours.	9
296	Brain Codelivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy. 2203958	3
295	Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields.	0
294	Lighting a Fire: Gasdermin-Mediated Pyroptosis Remodels the Glioma Microenvironment and Promotes Immune Checkpoint Blockade Response. 13,	0
293	Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches. <b>2022</b> , 39,	2
292	Intrathecal methotrexate in combination with systemic chemotherapy in glioblastoma patients with leptomeningeal dissemination: A retrospective analysis. <b>2022</b> , 10, 5595-5605	
291	The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study.	
290	Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. <b>2022</b> , 182, 106316	
289	Oncology and mechanics: Landmark studies and promising clinical applications. <b>2022</b> ,	0
288	Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.	1
287	Glioblastoma, from disease understanding towards optimal cell-based in vitro models.	1
286	A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony Stimulating Factor/Cyclophosphamide/Bevacizumab/Cembicizumab in Patients Who Failed First Treatment With Surgical Resection, Radiation, and Temozolomide.	0
285	Glioblastoma Treatment: State-of-the-Art and Future Perspectives. <b>2022</b> , 23, 7207	3
284	Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives. <b>2022</b> , 23, 7046	2
283	Updates in the Management of Recurrent Glioblastoma Multiforme.	1
282	The role of liquid biopsy in the diagnosis of glioblastoma progression. <b>2022</b> , 21, 104-116	
281	Obstacles to Glioblastoma Treatment Two Decades after Temozolomide. <b>2022</b> , 14, 3203	4
280	S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas. <b>2022</b> ,	



279	Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. <b>2022</b> , 15,	2
278	A phase II pilot randomized controlled trial to assess the feasibility of the supra-marginal surgical resection of malignant glioma (G-SUMIT: Glioma supra marginal incision trial) study protocol. <b>2022</b> , 8,	0
277	Electric Field Responsive Nanotransducers for Glioblastoma.	
276	Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review). <b>2022</b> , 61,	0
275	Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell-based therapeutic approaches.	0
274	Planning system for the optimization of electric field delivery using implanted electrodes for brain tumor control.	1
273	The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.	0
272	The mechanisms of action of Tumor Treating Fields.	1
271	Combining TMZ and SB225002 induces changes of CXCR2 and VEGFR signalling in primary human endothelial cells in vitro. <b>2022</b> , 48,	1
270	Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma.	
269	CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia-induced invasion, and therapeutic resistance.	
268	Temperature and Impedance Variations During Tumor Treating Fields (TTFields) Treatment. 16,	1
267	Boosting the anti-tumor performance of disulfiram against glioblastoma by using ultras-small nanoparticles and HIF-1 $\alpha$ inhibitor. <b>2022</b> , 243, 110117	0
266	Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures. <b>2022</b> , 109, 108929	0
265	Combination therapy with interferon-gamma as a potential therapeutic medicine in rat's glioblastoma: A multi-mechanism evaluation. <b>2022</b> , 305, 120744	
264	Indocarbocyanine nanoparticles extravasate and distribute better than liposomes in brain tumors. <b>2022</b> , 349, 413-424	
263	Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment. <b>2022</b> , 188, 114415	1
262	Static or 50 Hz magnetic fields at 100 $\mu$ T do not modify the clonogenic survival of doxorubicin-treated MCF-7 cancer cells. <b>2022</b> , 147, 108196	

261	Genetic Alteration May Proceed with a Histological Change in Glioblastoma: A Report from Initially Diagnosed as Nontumor Lesion Cases. <b>2022</b> , 9, 199-208	
260	Tumors of the nervous system. <b>2023</b> , 203-228	
259	A phase I/II study of triple-mutated oncolytic herpes virus G47 $\Delta$ in patients with progressive glioblastoma. <b>2022</b> , 13,	5
258	Intratumoral oncolytic herpes virus G47 $\Delta$ for residual or recurrent glioblastoma: a phase 2 trial.	13
257	Radiogenomics to characterize the immune-related prognostic signature associated with biological functions in glioblastoma.	0
256	MicroRNA-575 acts as a novel oncogene via targeting multiple signaling pathways in glioblastoma. <b>2022</b> , 104813	0
255	Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma. <b>2022</b> , 10, 1763	0
254	Skull defect increases the tumor treating fields strength without detrimental thermogenic effect: A computational simulating research.	
253	TRAF4 maintains deubiquitination of Caveolin-1 to drive glioblastoma stemness and Temozolomide resistance.	0
252	Perfluorocarbon Nanodroplets as Potential Nanocarriers for Brain Delivery Assisted by Focused Ultrasound-Mediated Blood-Brain Barrier Disruption. <b>2022</b> , 14, 1498	0
251	Tumor-targeting cell-penetrating peptide, p28, for glioblastoma imaging and therapy. 12,	0
250	Risk of Developing Non-Cancerous Central Nervous System Diseases Due to Ionizing Radiation Exposure during Adulthood: Systematic Review and Meta-Analyses. <b>2022</b> , 12, 984	1
249	Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities. 13,	1
248	Applications of Artificial Intelligence Based on Medical Imaging in Glioma: Current State and Future Challenges. 12,	2
247	MAIT cells and MR1 play an immunosuppressive role in glioblastoma through the induction of neutrophils and MDSCs.	
246	Characteristics and trends of globally registered glioma clinical trials in the past 16 years. <b>2022</b> , 15, 175628642211143	
245	Supportive and Palliative Care in Cancer Therapies: Path from Tumor-Driven Therapies to Patient-Driven Ones. <b>2022</b> , 13, 287-359	
244	Tumour treating fields. <b>2022</b> , 269-283	

243	The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics. <b>2022</b> , 9,	0
242	Tumor-Treating Fields in Glioblastomas: Past, Present, and Future. <b>2022</b> , 14, 3669	2
241	Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma. <b>2022</b> , 14, 3705	2
240	Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma.	
239	Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?. 12,	0
238	An implantable ultrasound-powered device for the treatment of brain cancer using electromagnetic fields. <b>2022</b> , 8,	0
237	Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data. 12,	
236	A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma. 10,	
235	The Role of Non-Coding RNAs in Glioma. <b>2022</b> , 10, 2031	2
234	Sex-specific T cell exhaustion drives differential immune responses in glioblastoma.	
233	Modulation of Tumor Treating Fields by Cerebral Edema from Brain Tumors. <b>2022</b> , 101046	
232	Remotely controlled near-infrared-triggered photothermal treatment of brain tumours in freely behaving mice using gold nanostars.	2
231	Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma. <b>2022</b> , 13,	0
230	Posaconazole inhibits the stemness of cancer stem-like cells by inducing autophagy and suppressing the Wnt/βcatenin/survivin signaling pathway in glioblastoma. 13,	0
229	Suppressor of fused associates with dissemination patterns in patients with glioma. 12,	
228	Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. 1-24	1
227	STAT3-mediated upregulation of LINC00520 contributed to temozolomide chemoresistance in glioblastoma by interacting with RNA-binding protein LIN28B. <b>2022</b> , 22,	1
226	Glioblastoma in Elderly Population.	

- 225 Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial. 13, 1
- 224 Early Diagnosis and Surgical Intervention Within 3 Weeks From Symptom Onset Are Associated With Prolonged Survival of Patients With Glioblastoma. **2022**, Publish Ahead of Print, 0
- 223 In-Vitro Use of Verteporfin for Photodynamic Therapy in Glioblastoma. **2022**, 103049 1
- 222 Predictive value of focal adhesion-related genes for prognosis and response to immunotherapy in glioma patients. 0
- 221 Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies. 0
- 220 Translational Significance of CDKN2A/B Homozygous Deletion in IDH-Mutant Astrocytoma. 0
- 219 Canine Glioma as a Model for Human Glioblastoma. 0
- 218 FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma. **2022**, 23, 8675 0
- 217 Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. 2
- 216 PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells. 12, 0
- 215 Use of heparin to rescue immunosuppressive monocyte reprogramming by glioblastoma-derived extracellular vesicles. **2022**, 1-11 0
- 214 TUG1/MAZ/FTH1 Axis Attenuates the Antiglioma Effect of Dihydroartemisinin by Inhibiting Ferroptosis. **2022**, 2022, 1-28 0
- 213 Dexamethasone and compliance affect TTFIELDS efficacy to glioblastoma patients: a systematic review and meta-analysis. **2022**, 8, 0
- 212 Overview of pathology and treatment of primary brain tumours. **2022**, 9-24 0
- 211 Modern advances in molecular and cellular biology in the treatment of glioblastoma. **2022**, 11, 66 0
- 210 Photodynamic Therapy Enhances the Cytotoxicity of Temozolomide Against Glioblastoma Via Reprogramming Anaerobic Glycolysis. 0
- 209 Biomedical applications of terahertz spectra in clinical and molecular pathology of human glioma. **2023**, 285, 121933 1
- 208 Hurdling over the blood-brain barrier with exosome technology. 0

207	Real-Time Monitoring of the Effect of Tumour-Treating Fields on Cell Division Using Live-Cell Imaging. <b>2022</b> , 11, 2712	0
206	Bioactive peptides from venoms against glioma progression. 12,	0
205	Protein Quality Control in Glioblastoma: A Review of the Current Literature with New Perspectives on Therapeutic Targets. <b>2022</b> , 23, 9734	1
204	Postoperative communicating hydrocephalus following glioblastoma resection: Incidence, timing and risk factors. 12,	0
203	Determinants of Tumor Treating Field Usage in Patients with Primary Glioblastoma: A Single Institutional Experience.	0
202	Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients. 12,	0
201	Clinical management of brain tumors in pregnancy. Publish Ahead of Print,	0
200	The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model. <b>2022</b> , 23, 9965	1
199	A Case of Glioblastoma, Isocitrate Dehydrogenase Wild Type, With Widely Disseminated Osseous Metastasis. <b>2022</b> ,	0
198	LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization. <b>2022</b> , 10, e004452	0
197	Metabolic remodeling of pyrimidine synthesis pathway and serine synthesis pathway in human glioblastoma. <b>2022</b> , 12,	0
196	Antimicrobial drug use and the risk of glioma: A case-control study.	0
195	Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood-Brain Barrier In Vitro and In Vivo. <b>2022</b> , 12, 1348	1
194	Role of the circulatory interleukin-6 in the pathogenesis of gliomas: A systematic review. <b>2022</b> , 12, 428-437	0
193	Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.	0
192	The impact of tumor metabolic activity assessed by <sup>18</sup> F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients. 12,	0
191	Identification and Verification of an Alternative Polyadenylation-Related lncRNA Prognostic Signature for Glioma. <b>2022</b> , 2022, 1-15	0
190	Single cell spatial analysis identifies regulators of brain tumor initiating cells.	0

189	From protein-protein interactions to immune modulation: Therapeutic prospects of targeting Neuropilin-1 in high-grade glioma. 13,	0
188	A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art. 12,	0
187	SerpInB3 drives cancer stem cell survival in glioblastoma. <b>2022</b> , 40, 111348	1
186	Current therapeutic options for glioblastoma and future perspectives. 1-12	1
185	Response to Selpercatinib in a Patient With Recurrent Glioblastoma and RET Amplification. <b>2022</b> , 20, 966-971	0
184	Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth.	0
183	Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. 12,	0
182	Associations of miR-181a with Health-Related Quality of Life, Cognitive Functioning, and Clinical Data of Patients with Different Grade Glioma Tumors. <b>2022</b> , 23, 11149	0
181	The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers.	0
180	Detecting monocyte trafficking in an animal model of glioblastoma using R2* and quantitative susceptibility mapping.	0
179	Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of brain malignancies.	0
178	Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective. <b>2022</b> , 215945	0
177	Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy. <b>2022</b> , 108287	0
176	The Distinguishing Electrical Properties of Cancer Cells. <b>2022</b> ,	0
175	Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.	0
174	Brain-Targeting Metastatic Tumor Cell Membrane Cloaked Biomimetic Nanomedicines Mediate Potent Chemodynamic and RNAi Combinational Therapy of Glioblastoma. 2209239	2
173	BTB domain and CNC homolog 1 promotes glioma invasion mainly through regulating extracellular matrix and increases ferroptosis sensitivity. <b>2022</b> , 1868, 166554	0
172	A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.	0

171	Glioblastoma-Derived Three-Dimensional Ex Vivo Models to Evaluate Effects and Efficacy of Tumor Treating Fields (TTFields). <b>2022</b> , 14, 5177	0
170	Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19). <b>2022</b> , 13,	0
169	Spermidine/Spermine N1-Acetyltransferase 1 (SAT1) A Potential Gene Target for Selective Sensitization of Glioblastoma Cells Using an Ionizable Lipid Nanoparticle to Deliver siRNA. <b>2022</b> , 14, 5179	2
168	Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center. <b>2022</b> , 11, 5855	0
167	The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. <b>2022</b> , 23, 1566-1589	1
166	Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. <b>2022</b> , 12, 1426	0
165	Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape. 13,	0
164	Decision-Making Regarding Perioperative Therapy in Individuals with Localized Pancreatic Adenocarcinoma. <b>2022</b> , 36, 961-978	0
163	Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma. <b>2022</b> , 22,	0
162	Phase 2 Study of AV-GBM-1 (a Tumor-initiating Cell Targeted Dendritic Cell Vaccine) in Newly Diagnosed Glioblastoma Patients: Safety and Efficacy Assessment.	0
161	New Directions in the Therapy of Glioblastoma. <b>2022</b> , 14, 5377	2
160	Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin. <b>2022</b> , 23, 11629	1
159	Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?. <b>2022</b> , 14, 4960	2
158	The Oncogenesis of Glial Cells in Diffuse Gliomas and Clinical Opportunities.	0
157	Electric field responsive nanotransducers for glioblastoma. <b>2022</b> , 8,	0
156	Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization. <b>2022</b> , 22,	0
155	Preoperative stereotactic radiosurgery in the management of brain metastases and gliomas. 9,	0
154	Medical Device Advances in the Treatment of Glioblastoma. <b>2022</b> , 14, 5341	1

153	Glioblastoma cell motility depends on enhanced oxidative stress coupled with mobilization of a sulfurtransferase. <b>2022</b> , 13,	1
152	The peritumoral brain zone in glioblastoma: where we are and where we are going.	1
151	Natural killer cell immunotherapy in glioblastoma. <b>2022</b> , 13,	0
150	Primary Neoplasms of the Brain in Adults. 1-13	0
149	The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy. <b>2022</b> , 8,	1
148	Elucidating the cellular uptake mechanisms of heptamethine cyanine dye analogues for their use as an anticancer drug-carrier molecule for the treatment of glioblastoma.	0
147	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. 13,	0
146	Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial. <b>2022</b> , 24, S4-S15	0
145	Dual-drug loaded nanomedicine hydrogel as a therapeutic platform to target both residual glioblastoma and glioma stem cells. <b>2022</b> , 628, 122341	0
144	Deep learning characterization of brain tumours with diffusion weighted imaging. <b>2023</b> , 557, 111342	0
143	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. <b>2022</b> , 35, 803-813	2
142	Identification of tryptophan metabolic gene-related subtypes, development of prognostic models, and characterization of tumor microenvironment infiltration in gliomas. 15,	0
141	The role of RNA modification in the generation of acquired drug resistance in glioma. 13,	0
140	Targeting Heat Shock Proteins in Malignant Brain Tumors: From Basic Research to Clinical Trials. <b>2022</b> , 14, 5435	1
139	Challenges in glioblastoma research: focus on the tumor microenvironment. <b>2022</b> ,	0
138	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. 13,	0
137	A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution. 12,	0
136	Advances in molecular biomarkers and liquid biopsy in gliomas. <b>2022</b> , 4, ii15-ii21	0



135	Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.	1
134	Socioeconomic and demographic determinants of radiation treatment and outcomes in glioblastoma patients. 13,	0
133	Research on application of tumor treating fields in glioblastoma: A bibliometric and visual analysis. 12,	0
132	Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival. 2022, 13,	2
131	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. 13,	0
130	Oncolytic Zika Virus: New Option for Glioblastoma Treatment.	0
129	Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.	0
128	Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma. 2022, 32, 101386	0
127	Image-localized Biopsy Mapping of Brain Tumor Heterogeneity: A Single-Center Study Protocol.	0
126	RAGE Ablation Attenuates Glioma Progression and Enhances Tumor Immune Responses by Suppressing Galectin-3 Expression.	0
125	Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma.	7
124	Advances of Electroporation-Related Therapies and the Synergy with Immunotherapy in Cancer Treatment. 2022, 10, 1942	0
123	Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines. 2022, 12,	0
122	Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity.	0
121	Central nervous system tumors. 2022, 211-235	0
120	Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress. 2023, 157, 114037	0
119	Cancer immune profiling unveils biomarkers, immunological pathways, and cell type score associated with glioblastoma patients survival. 2022, 14, 175883592211276	0
118	The role of angiogenic factors eNOS / VEGF in the treatment of anaplastic glioma. 2022, 883-892	0

117	Standardizing Skullremodeling Surgery and Electrode Array Layout to Improve Tumor Treating Fields Using Computational Head Modeling and Finite Element Methods. <b>2023</b> , 19-35	0
116	The Impact of Scalp Temperature in the Predicted LMIPD in the Tumor During TTFields Treatment for Glioblastoma Multiforme. <b>2023</b> , 3-18	0
115	Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degradar for Glioblastoma. <b>2022</b> , 65, 15642-15662	1
114	A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. <b>2022</b> , 10, 2977	0
113	Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide. <b>2022</b> , 2022, 1-9	0
112	Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas from a radiation oncologist perspective.	0
111	Bottlenecks and opportunities in immunotherapy for glioma: a narrative review. Publish Ahead of Print,	0
110	Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. <b>2022</b> , 41,	1
109	Prognostic Value of Systemic Immune-Inflammation Index (SII) in Patients with Glioblastoma: A Comprehensive Study Based on Meta-Analysis and Retrospective Single-Center Analysis. <b>2022</b> , 11, 7514	0
108	Tumor Microenvironment and Microvascular Density in Human Glioblastoma. <b>2023</b> , 12, 11	1
107	Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.	4
106	????????????: ??????????, ??????????, ?????????? ???????, ??????????, ?????????? ??????????, ??????????. 13-26	0
105	Electricity-Assisted Cancer Therapy: From Traditional Clinic Applications to Emerging Methods Integrated with Nanotechnologies. 2200143	0
104	Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma. 12,	0
103	Tumoricidal, Temozolomide- and Radiation-Sensitizing Effects of KCa3.1 K+ Channel Targeting In Vitro Are Dependent on Glioma Cell Line and Stem Cell Fraction. <b>2022</b> , 14, 6199	0
102	Stelletin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair. 2205529	1
101	Intraoperative ventricular opening has no effect on complication development following BCNU wafer implantation for malignant glioma. <b>2022</b> ,	0
100	Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data. <b>2022</b> , 14, 6180	0

- 99 Gene Therapy for High Grade Glioma: The Clinical Experience. 1-17 ○
- 98 Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region. 12, ○
- 97 Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study. ○
- 96 Injectable local drug delivery systems for glioblastoma: a systematic review and meta-analysis of progress to date. ○
- 95 Tumor treating fields: a new treatment for glioblastoma. **2023**, 37, 58-63 ○
- 94 Signaling pathways in brain tumors and therapeutic interventions. **2023**, 8, ○
- 93 Targeted therapies in patients with newly diagnosed glioblastoma: a systematic meta-analysis of randomized clinical trials. ○
- 92 Dimorphic glioblastoma with glial and epithelioid phenotypes: Clonal evolution and immune selection. 13, ○
- 91 Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier. **2023**, 15, 185 1
- 90 Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort. 13, ○
- 89 Palliative care in brain tumors. **2023**, 69-80 ○
- 88 Photodynamic therapy for glioblastoma: A light at the end of the tunnel. **2023**, 13, 100161 ○
- 87 Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma. ○
- 86 Utility of the Cerebral Organoid Glioma (LICO) Model for Screening Applications. **2023**, 12, 153 ○
- 85 Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma. **2022**, 12, ○
- 84 Key Genes Are Associated with the Prognosis of Glioma, and Melittin Can Regulate the Expression of These Genes in Glioma U87 Cells. **2022**, 2022, 1-18 ○
- 83 Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas. **2023**, 15, 880 ○
- 82 Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment. **2023**, 15, 636 ○

- 81 Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review. **2023**, 13, 159 ○
- 80 Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022. ○
- 79 Eighteen years experience with tumor treating fields in the treatment of newly diagnosed glioblastoma. 12, ○
- 78 Editorial: Developmental therapeutics in pediatric neuro-oncology. 13, ○
- 77 Tumor Treating Fields delivered via electromagnetic induction have varied effects across glioma cell lines and electric field amplitudes. ○
- 76 Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis. **2023**, 11, e004805 ○
- 75 Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy. **2023**, 6, ○
- 74 Case report: Radiographic complete response of radiation-induced glioblastoma to front-line radiotherapy: A report and molecular characterization of two unique cases. 14, ○
- 73 Prognostic evaluation of patients with glioblastoma using a new score prediction model. **2023**, ○
- 72 Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival. ○
- 71 Biosynthesis and Significance of Fatty Acids, Glycerophospholipids, and Triacylglycerol in the Processes of Glioblastoma Tumorigenesis. **2023**, 15, 2183 ○
- 70 An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines. **2023**, 196, 114816 ○
- 69 Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis. **2023**, 42, 103342 1
- 68 oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy. **2023**, 29, 30-41 ○
- 67 The Impact of Scalp's Temperature on the Choice of the Best Layout for TTFIELDS Treatment. **2023**, 44, 100768 ○
- 66 Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. **2023**, 14, ○
- 65 Cancer-related protein profile of patient-derived and commercial glioblastoma cell lines exposed to Temozolomide. ○
- 64 Neuro-Oncology in Women. **2023**, 41, 331-342 ○

- 63 Natural Killer Cell-Based Immunotherapy against Glioblastoma. **2023**, 24, 2111 ○
- 62 CKAP4-mediated activation of FOXM1 via phosphorylation pathways regulates malignant behavior of glioblastoma cells. **2023**, 29, 101628 ○
- 61 Next-generation antigen-presenting cell immune therapeutics for gliomas. **2023**, 133, 1
- 60 Superenhancers as master gene regulators and novel therapeutic targets in brain tumors. **2023**, 55, 290-303 ○
- 59 Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant Temozolomide. **2023**, 13, e239-e245 ○
- 58 Temozolomide Chronotherapy in Glioma: A Systematic Review. **2023**, 30, 1893-1902 ○
- 57 A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma. **2023**, 9, 362-374 ○
- 56 Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells. **2023**, 24, 3199 ○
- 55 Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. ○
- 54 Consultation with a neurosurgeon upon initial medical assessment is associated with improved prognosis of glioblastoma patients. ○
- 53 Modulation of blood-brain tumor barrier for delivery of magnetic hyperthermia to brain cancer. **2023**, 355, 248-258 ○
- 52 Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling. **2023**, 21, ○
- 51 Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas. ○
- 50 IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. **2023**, 11, e006239 ○
- 49 Letter to the Editor Regarding Global Research Trends in Radiotherapy for Gliomas: A Systematic Bibliometric Analysis **2023**, 170, 251 ○
- 48 The Immunology of Brain Tumors. **2023**, ○
- 47 Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas. **2023**, 165, 693-699 ○
- 46 Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience. **2023**, 15, 1194 ○

- 45 Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy. **2023**, 15, ○
- 44 Modeling glioblastoma complexity with organoids for personalized treatments. **2023**, 29, 282-296 ○
- 43 Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. **2023**, 42, 112127 ○
- 42 Antitumor Potential of Antiepileptic Drugs in Human Glioblastoma: Pharmacological Targets and Clinical Benefits. **2023**, 11, 582 ○
- 41 Association between systemic immune-inflammation index (SII) and survival outcome in patients with primary glioblastoma. **2023**, 102, e33050 ○
- 40 Glioblastoma and Other Primary Brain Malignancies in Adults. **2023**, 329, 574 ○
- 39 Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging. **2023**, 18, ○
- 38 Top advances of the year: Neuro-oncology. ○
- 37 Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases. **2023**, 13, ○
- 36 Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma. ○
- 35 Epithelial-Mesenchymal Transition Expression Profile Stratifies Human Glioma into Two Distinct Tumor-Immune Subtypes. **2023**, 13, 447 ○
- 34 Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas. **2023**, 24, 5016 ○
- 33 Antisense lncRNA CHROMR is linked to glioma patient survival. 10, ○
- 32 Diagnosis and comprehensive treatment of pancreatic glucagonoma presenting with multiple metastases and recurring postoperatively. ○
- 31 Identification of Genetic Alterations in Rapid Progressive Glioblastoma by Use of Whole Exome Sequencing. **2023**, 13, 1017 ○
- 30 Spatiotemporally dynamic electric fields for brain cancer treatment: an in vitro investigation. **2023**, 68, 085012 ○
- 29 Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. **2023**, 12, 843 ○
- 28 Frequency and Prognostic Relevance of Volumetric MRI Changes in Contrast- and Non-Contrast-Enhancing Tumor Compartments between Surgery and Radiotherapy of IDHwt Glioblastoma. **2023**, 15, 1745 ○

- 27 Intelligent medicine and beyond. **2023**, 68, 1165-1181 ○
- 26 Interstitial photodynamic therapy for newly diagnosed glioblastoma. **2023**, 162, 217-223 ○
- 25 Effect of re-irradiation at bevacizumab failure in recurrent glioblastoma: a comparative analysis with maintenance bevacizumab. ○
- 24 Ion channels as molecular targets of glioblastoma electrotherapy. 17, ○
- 23 circMMD reduction following tumor treating fields inhibits glioblastoma progression through FUBP1/FIR/DVL1 and miR-15b-5p/FZD6 signaling. **2023**, 42, ○
- 22 LINC01393, a Novel Long Non-Coding RNA, Promotes the Cell Proliferation, Migration and Invasion through MiR-128-3p/NUSAP1 Axis in Glioblastoma. **2023**, 24, 5878 ○
- 21 ChatGPT in glioma patient adjuvant therapy decision making: ready to assume the role of a doctor in the tumour board?. ○
- 20 Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex. **2023**, 162, 167-177 ○
- 19 Demographic variations and time to initiation of adjunct treatment following surgical resection of anaplastic astrocytoma in the United States: a National Cancer Database analysis. **2023**, 162, 199-210 ○
- 18 Multimodal MRI Brain Tumor Segmentation using 3D Attention UNet with Dense Encoder Blocks and Residual Decoder Blocks. ○
- 17 The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens. **2023**, 15, 2024 ○
- 16 Therapeutic potential of tumor treating fields for malignant brain tumors. ○
- 15 IL13R $\alpha$ -targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy. ○
- 14 Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies. ○
- 13 Updates on Role for and Efficacy of Laser Interstitial Thermal Therapy in the Management of Brain Tumors. **2023**, 3, 87-96 ○
- 12 Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma. ○
- 11 TTFIELDS Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report. **2023**, 13, 633 ○
- 10 Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. **2023**, 21, ○

- 9 Overcoming the blood brain barrier in glioblastoma: Status and future perspective. **2023**, ○
- 8 Personalised therapeutic approaches to glioblastoma: A systematic review. 10, ○
- 7 Gene Targets of CAR-T Cell Therapy for Glioblastoma. **2023**, 15, 2351 ○
- 6 Re-Irradiation Combined with Bevacizumab for Recurrent Glioblastoma beyond Bevacizumab Failure: Survival Outcomes and Prognostic Factors. ○
- 5 Understanding the activity of antibodydrug conjugates in primary and secondary brain tumours. ○
- 4 Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine. ○
- 3 Piezoelectric Nanomaterials Activated by Ultrasound in Disease Treatment. **2023**, 15, 1338 ○
- 2 Combination of local immunogenic cell death-inducing chemotherapy and DNA vaccine increases the survival of glioblastoma-bearing mice. **2023**, 50, 102681 ○
- 1 Technical report: surgical preparation of human brain tissue for clinical and basic research. ○